[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fs_AfLImRIOa9qy-lYtMagBOr0Lq-T5GQvCLI-grnJbc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Vanderbilt-Ingram Cancer Center",[4],216,false,37,4,64110,35,78,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Breast Cancer",27,{"name":18,"count":19},"Lung Cancer",24,{"name":21,"count":22},"Head and Neck Cancer",22,{"name":24,"count":25},"Lymphoma",10,{"name":27,"count":25},"Solid Tumor",{"name":29,"count":30},"Colorectal Cancer",9,{"name":32,"count":33},"Myelodysplastic Syndromes",7,{"name":35,"count":33},"Leukemia",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01791478","BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer","2014-12","PI3K inhibitor BYL719",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04454476","Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor","2024-12","Trametinib treatment",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03694249","Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence","2025-04","Ifetroban Sodium",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05501665","Split Course Adaptive Radiation Therapy With Pembrolizumab With\u002FWithout Chemotherapy for Treating Stage IV Lung Cancer","2026-02-01","Carboplatin",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05361720","Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study","2026-10-01","Cabozantinib",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05996432","Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy","2026-11-30","18F-fluoromisonidazole",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT00898313","Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer","2027-01-31","comparative genomic hybridization",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06399640","Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia","2027-02-01","Eltanexor",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","2027-05-28","Lutetium Lu 177 Dotatate",{"nctId":83,"briefTitle":84,"date":85,"intervention":56},"NCT06110572","Phase I\u002FII Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","2027-06-30",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,125,143,264,378,420,471,493,515,537,564,582,604,632,650,668,686,791,842,882,900,918,942,967,994,1012,1030,1056,1085,1106,1217,1288,1322,1351,1369,1387,1414,1441,1459,1482,1515,1533,1551,1569,1587,1605,1665,1734,1788,1835,1872,1910,1940,1966,2000,2026,2067,2137,2162,2203,2244,2271,2293,2315,2337,2361,2379,2406,2424,2450,2468,2486,2504,2522,2547,2570,2600,2624,2642,2660,2678,2696,2722,2740,2764,2782,2804,2828,2846,2864,2897,2915,2939,2957,2984,3010,3028,3046,3070,3100,3118,3136,3161,3179,3197,3215,3233,3251,3269,3287,3305,3328,3354,3382,3410,3432,3456,3474,3492,3510,3528,3546,3564,3582,3605,3627,3652,3670,3693,3711,3737,3755,3773,3791,3817,3835,3853,3876,3912,3930,3960,3983,4013,4062,4100,4139,4185,4207,4229,4251,4269,4296,4314,4332,4357,4375,4399,4417,4435,4453,4471,4489,4507,4537,4555,4576,4600,4618,4636,4654,4672,4690,4708,4726,4748,4766,4790,4808,4826,4851,4869],{"intervention":81,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":123},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":80},[108],{"nctId":78,"briefTitle":79,"status":109,"phases":110,"primaryCompletion":80,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":121},"RECRUITING",[91],"2028-05-28","2024-05-31",6,[115,116,117,118,119,120],"Digestive System Neuroendocrine Tumor G1","Digestive System Neuroendocrine Tumor G2","Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Malignant Neoplasm in the Liver","Pancreatic Neuroendocrine Tumor G1","Pancreatic Neuroendocrine Tumor G2",[81,122],"Copper Cu 64 Dotatate",{"trials":124,"activeCount":99},[],{"intervention":122,"totalTrials":95,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":141},{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":99},[],{"trials":132,"activeCount":99},[],{"trials":134,"activeCount":99},[],{"trials":136,"activeCount":95,"soonestReadout":80},[137],{"nctId":78,"briefTitle":79,"status":109,"phases":138,"primaryCompletion":80,"completion":111,"start":112,"enrollment":113,"conditions":139,"interventions":140},[91],[115,116,117,118,119,120],[81,122],{"trials":142,"activeCount":99},[],{"intervention":144,"totalTrials":33,"cells":145},"Nivolumab",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":202,"PHASE3":258,"PHASE4":260,"NA":262},{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":95,"soonestReadout":184},[150,164,179],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":99,"conditions":158,"interventions":162},"NCT03652233","Afatinib and Nivolumab as Treatment for Recurrent\u002FMetastatic Squamous Cell Carcinoma of the Head and Neck","WITHDRAWN",[88],"2021-11","2022-11","2018-11-02",[159,160,161],"Recurrent Squamous Cell Carcinoma of the Head or Neck","Metastatic Squamous Cell Carcinoma of the Head or Neck","Squamous Cell Carcinoma",[144,163],"Afatinib",{"nctId":165,"briefTitle":166,"status":167,"phases":168,"primaryCompletion":169,"completion":169,"start":170,"enrollment":113,"conditions":171,"interventions":176},"NCT03558750","Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma","TERMINATED",[88],"2019-04-16","2018-06-14",[172,173,174,175],"Recurrent Central Nervous System Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Refractory Central Nervous System Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",[144,177,178],"Rituximab","Lenalidomide",{"nctId":180,"briefTitle":181,"status":182,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":200},"NCT07460765","Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)","NOT_YET_RECRUITING",[88],"2030-04","2031-04","2026-04-30",40,[189,190,191,192,193,194,195,196,197,198,199],"Hnscc","Head and Neck","Squamous Cell Cancer","Squamous Carcinoma","Squamous Cell Cancer of Head and Neck (SCCHN)","Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","Squamous Cell Carcinoma Mouth","Squamous Carcinoma Poorly Differentiated","Squamous Cell Cancer of the Head and Neck","Squamous Cell Carcinoma (SCC) of the Oral Cavity","Squamous Cell Carcinoma (SCC)",[201,144],"Nivo800",{"trials":203,"activeCount":257,"soonestReadout":55},[204,220,232,246],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":218},"NCT03583086","Phase I\u002FII Eval Safety & Prelim Activity Nivolumab Comb W\u002FVorolanib Pts W\u002FRefractory Thoracic Tumors","COMPLETED",[88,89],"2024-02-21","2024-04-27","2018-07-10",88,[214,215,216,217],"Thymic Carcinoma","Non-small Cell Lung Cancer","Refractory Thoracic Tumors","Small-Cell Lung Cancer",[219,144],"Vorolanib",{"nctId":58,"briefTitle":59,"status":109,"phases":221,"primaryCompletion":60,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":230},[89],"2027-07-01","2022-12-06",54,[226,227,228,229],"Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[61,231,144],"Ipilimumab",{"nctId":53,"briefTitle":54,"status":109,"phases":233,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":236,"interventions":240},[88,89],"2023-05-09",25,[237,238,239],"Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage III Lung Cancer",[56,241,242,243,231,144,244,245],"Nab-paclitaxel","Pembrolizumab","Pemetrexed","Cemiplimab","Atezolizumab",{"nctId":247,"briefTitle":248,"status":153,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":99,"conditions":253,"interventions":256},"NCT03023904","Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads",[89],"2019-07-30","2020-07-30","2017-12-29",[254,255],"Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer",[144],2,{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":99},[],{"intervention":56,"totalTrials":30,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"trials":271,"activeCount":257,"soonestReadout":55},[272,289,299,311,323,327,337,348,362],{"nctId":273,"briefTitle":274,"status":207,"phases":275,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":281},"NCT00550537","Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[89],"2011-09","2013-12","2007-10",116,[18],[282,283,284,285,286,287,288],"bevacizumab","carboplatin","erlotinib hydrochloride","paclitaxel","gene expression analysis","protein expression analysis","proteomic profiling",{"nctId":83,"briefTitle":84,"status":109,"phases":290,"primaryCompletion":85,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},[88,89],"2028-06-30","2024-04-24",18,[295,296],"Extensive Stage Lung Small Cell Carcinoma","Stage IV Lung Cancer",[56,245,298],"Etoposide",{"nctId":300,"briefTitle":301,"status":153,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":99,"conditions":305,"interventions":308},"NCT01928160","Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib",[89],"2015-03","2014-06",[306,307],"Recurrent Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[309,283,310,284],"pemetrexed disodium","cisplatin",{"nctId":312,"briefTitle":313,"status":167,"phases":314,"primaryCompletion":315,"completion":315,"start":316,"enrollment":95,"conditions":317,"interventions":321},"NCT06140407","Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer",[89],"2025-05-27","2024-02-14",[318,319,320,239],"Limited Stage Lung Small Cell Carcinoma","Stage I Lung Cancer","Stage II Lung Cancer",[322,56,298,242],"Cisplatin",{"nctId":53,"briefTitle":54,"status":109,"phases":324,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":325,"interventions":326},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"nctId":328,"briefTitle":329,"status":167,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT00544648","Ph I\u002FII Nab-Paclitaxel & Carboplatin w\u002FConcurrent Radiation Therapy for Unresectable Stg III NSCLC",[88,89],"2014-04","2007-11",13,[18],[283,336],"nab-paclitaxel",{"nctId":338,"briefTitle":339,"status":207,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":346},"NCT00469898","Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[89],"2008-07","2010-07","2003-12",50,[18],[56,347],"irinotecan hydrochloride",{"nctId":349,"briefTitle":350,"status":207,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":361},"NCT03206203","Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer",[89],"2022-11-30","2023-10-04","2017-08-29",106,[357,358,359,360],"Triple Negative Breast Cancer","Stage IV Breast Cancer","HER2 Negative","Invasive Breast Cancer",[245,56],{"nctId":363,"briefTitle":364,"status":167,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT00664105","Ph II Concurrent Chemo t\u002FDocetaxel\u002FCarboplatin\u002FRadio Therapy-consolidation t\u002FLocally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)",[89],"2008-06","2004-02",63,[18],[56,371],"Docetaxel",{"trials":373,"activeCount":99},[],{"trials":375,"activeCount":99},[],{"trials":377,"activeCount":99},[],{"intervention":245,"totalTrials":9,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":257,"soonestReadout":55},[386,390,394,398],{"nctId":83,"briefTitle":84,"status":109,"phases":387,"primaryCompletion":85,"completion":291,"start":292,"enrollment":293,"conditions":388,"interventions":389},[88,89],[295,296],[56,245,298],{"nctId":53,"briefTitle":54,"status":109,"phases":391,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":392,"interventions":393},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"nctId":349,"briefTitle":350,"status":207,"phases":395,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":396,"interventions":397},[89],[357,358,359,360],[245,56],{"nctId":399,"briefTitle":400,"status":167,"phases":401,"primaryCompletion":402,"completion":402,"start":211,"enrollment":403,"conditions":404,"interventions":411},"NCT03566485","Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer",[88,89],"2020-12-10",12,[405,406,407,408,358,409,410],"Stage III Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Estrogen Receptor-positive","HER2\u002FNeu Negative",[245,412,413],"Cobimetinib","Idasanutlin",{"trials":415,"activeCount":99},[],{"trials":417,"activeCount":99},[],{"trials":419,"activeCount":99},[],{"intervention":242,"totalTrials":9,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":423,"activeCount":99},[],{"trials":425,"activeCount":99},[],{"trials":427,"activeCount":257,"soonestReadout":55},[428,432,446,450],{"nctId":312,"briefTitle":313,"status":167,"phases":429,"primaryCompletion":315,"completion":315,"start":316,"enrollment":95,"conditions":430,"interventions":431},[89],[318,319,320,239],[322,56,298,242],{"nctId":433,"briefTitle":434,"status":167,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":445},"NCT02359851","Pembrolizumab in Treating Patients With Advanced Uveal Melanoma",[89],"2017-05","2019-08-27","2015-05",5,[441,442,443,444],"Stage IIIA Uveal Melanoma","Stage IIIB Uveal Melanoma","Stage IIIC Uveal Melanoma","Stage IV Uveal Melanoma",[242],{"nctId":53,"briefTitle":54,"status":109,"phases":447,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":448,"interventions":449},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"nctId":451,"briefTitle":452,"status":453,"phases":454,"primaryCompletion":455,"completion":456,"start":234,"enrollment":33,"conditions":457,"interventions":463},"NCT05764395","Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable\u002FMetastatic Melanoma Refractory to PD-1 Inhibitors","ACTIVE_NOT_RECRUITING",[89],"2028-05-01","2029-05-01",[458,459,460,461,462],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Melanoma","Refractory Melanoma","Unresectable Melanoma",[464,242],"Rigosertib",{"trials":466,"activeCount":99},[],{"trials":468,"activeCount":99},[],{"trials":470,"activeCount":99},[],{"intervention":231,"totalTrials":257,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":99},[],{"trials":478,"activeCount":257,"soonestReadout":55},[479,483],{"nctId":58,"briefTitle":59,"status":109,"phases":480,"primaryCompletion":60,"completion":222,"start":223,"enrollment":224,"conditions":481,"interventions":482},[89],[226,227,228,229],[61,231,144],{"nctId":53,"briefTitle":54,"status":109,"phases":484,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":485,"interventions":486},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":99},[],{"trials":492,"activeCount":99},[],{"intervention":298,"totalTrials":257,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":95,"soonestReadout":85},[501,505],{"nctId":83,"briefTitle":84,"status":109,"phases":502,"primaryCompletion":85,"completion":291,"start":292,"enrollment":293,"conditions":503,"interventions":504},[88,89],[295,296],[56,245,298],{"nctId":312,"briefTitle":313,"status":167,"phases":506,"primaryCompletion":315,"completion":315,"start":316,"enrollment":95,"conditions":507,"interventions":508},[89],[318,319,320,239],[322,56,298,242],{"trials":510,"activeCount":99},[],{"trials":512,"activeCount":99},[],{"trials":514,"activeCount":99},[],{"intervention":241,"totalTrials":257,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":95,"soonestReadout":55},[523,527],{"nctId":53,"briefTitle":54,"status":109,"phases":524,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":525,"interventions":526},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"nctId":328,"briefTitle":329,"status":167,"phases":528,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":529,"interventions":530},[88,89],[18],[283,336],{"trials":532,"activeCount":99},[],{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"intervention":538,"totalTrials":95,"cells":539},"Sacituzumab Govitecan",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":95,"soonestReadout":550},[546],{"nctId":547,"briefTitle":548,"status":109,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":557},"NCT05770531","Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy",[89],"2028-08-01","2028-10-01","2023-08-04",160,[555,556],"Metastatic HER2-Negative Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma",[538],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":99},[],{"intervention":61,"totalTrials":95,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":99},[],{"trials":571,"activeCount":95,"soonestReadout":60},[572],{"nctId":58,"briefTitle":59,"status":109,"phases":573,"primaryCompletion":60,"completion":222,"start":223,"enrollment":224,"conditions":574,"interventions":575},[89],[226,227,228,229],[61,231,144],{"trials":577,"activeCount":99},[],{"trials":579,"activeCount":99},[],{"trials":581,"activeCount":99},[],{"intervention":51,"totalTrials":95,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[],{"trials":589,"activeCount":95,"soonestReadout":50},[590],{"nctId":48,"briefTitle":49,"status":453,"phases":591,"primaryCompletion":50,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":597},[89],"2026-04","2018-12-12",30,[596],"Malignant Solid Tumor",[51],{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[],{"intervention":605,"totalTrials":95,"cells":606},"Neratinib",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":95,"soonestReadout":617},[613],{"nctId":614,"briefTitle":615,"status":109,"phases":616,"primaryCompletion":617,"completion":618,"start":619,"enrollment":594,"conditions":620,"interventions":625},"NCT05919108","Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers",[89],"2030-04-30","2031-04-30","2024-05-30",[621,622,623,624],"Anatomic Stage I Breast Cancer","Anatomic Stage II Breast Cancer","Anatomic Stage III Breast Cancer","Invasive Breast Lobular Carcinoma",[605],{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":99},[],{"intervention":243,"totalTrials":95,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":635,"activeCount":99},[],{"trials":637,"activeCount":99},[],{"trials":639,"activeCount":95,"soonestReadout":55},[640],{"nctId":53,"briefTitle":54,"status":109,"phases":641,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":642,"interventions":643},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"trials":645,"activeCount":99},[],{"trials":647,"activeCount":99},[],{"trials":649,"activeCount":99},[],{"intervention":244,"totalTrials":95,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":662,"PHASE4":664,"NA":666},{"trials":653,"activeCount":99},[],{"trials":655,"activeCount":99},[],{"trials":657,"activeCount":95,"soonestReadout":55},[658],{"nctId":53,"briefTitle":54,"status":109,"phases":659,"primaryCompletion":55,"completion":75,"start":234,"enrollment":235,"conditions":660,"interventions":661},[88,89],[237,238,239],[56,241,242,243,231,144,244,245],{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":99},[],{"trials":667,"activeCount":99},[],{"intervention":464,"totalTrials":95,"cells":669},{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":680,"PHASE4":682,"NA":684},{"trials":671,"activeCount":99},[],{"trials":673,"activeCount":99},[],{"trials":675,"activeCount":95,"soonestReadout":455},[676],{"nctId":451,"briefTitle":452,"status":453,"phases":677,"primaryCompletion":455,"completion":456,"start":234,"enrollment":33,"conditions":678,"interventions":679},[89],[458,459,460,461,462],[464,242],{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"intervention":687,"totalTrials":688,"cells":689},"letrozole",8,{"EARLY_PHASE1":690,"PHASE1":713,"PHASE2":740,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":691,"activeCount":99},[692,701],{"nctId":693,"briefTitle":694,"status":167,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":700},"NCT00651976","Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",[87],"2018-09","2008-03",213,[15],[687],{"nctId":702,"briefTitle":703,"status":207,"phases":704,"primaryCompletion":705,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},"NCT03962647","A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer",[87],"2024-03-07","2024-07-14","2019-07-08",31,[710],"Estrogen Receptor-positive Breast Cancer",[712],"Letrozole",{"trials":714,"activeCount":95,"soonestReadout":40},[715,726],{"nctId":38,"briefTitle":39,"status":453,"phases":716,"primaryCompletion":40,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":725},[88],"2025-02-28","2013-04",46,[710,721,722,723,724,358],"HER2-negative Breast Cancer","Invasive Ductal Breast Carcinoma","Progesterone Receptor-positive Breast Cancer","Recurrent Breast Cancer",[41,687],{"nctId":727,"briefTitle":728,"status":207,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":736},"NCT01248494","PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer",[88],"2012-12","2016-05","2010-11",72,[735],"Metastatic Breast Cancer",[737,738,712,739],"BEZ235","BKM 120","BKM120",{"trials":741,"activeCount":99},[742,755,765,775],{"nctId":743,"briefTitle":744,"status":167,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":751},"NCT01205685","Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer",[89],"2011-07","2010-05",11,[750],"Hormone-sensitive Metastatic Breast Cancer",[752,753,712,754],"OSI-906","Erlotinib","Goserelin",{"nctId":756,"briefTitle":757,"status":167,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":763},"NCT00611715","Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w\u002F ER and\u002For PR-positive Met Breast Cancer.",[89],"2008-12","2003-11",48,[15],[284,687,764],"fluorescence in situ hybridization",{"nctId":766,"briefTitle":767,"status":167,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":113,"conditions":772,"interventions":773},"NCT00499681","PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w\u002FHER2+ & Hormone Receptor+ Operable Breast CA SPORE",[89],"2009-10","2010-12","2007-07",[15],[774,687],"lapatinib ditosylate",{"nctId":776,"briefTitle":777,"status":153,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":99,"conditions":781,"interventions":782},"NCT01013506","Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer",[89],"2009-12","2009-08",[15],[783,284,784,687],"IGF-1R inhibitor OSI-906","goserelin",{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":99},[],{"intervention":792,"totalTrials":793,"cells":794},"cetuximab",3,{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":824,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":796,"activeCount":99},[],{"trials":798,"activeCount":95,"soonestReadout":803},[799,814],{"nctId":800,"briefTitle":801,"status":109,"phases":802,"primaryCompletion":803,"completion":804,"start":805,"enrollment":235,"conditions":806,"interventions":811},"NCT07217028","Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and\u002For Metastatic Disease in Head and Neck Squamous Cell Carcinoma",[88],"2029-04","2030-09","2026-04-24",[807,808,809,810],"SCC - Squamous Cell Carcinoma","Radiotracer","Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma",[812,813],"Cetuximab","18F-NOTA-ABY-030",{"nctId":815,"briefTitle":816,"status":207,"phases":817,"primaryCompletion":818,"completion":278,"start":819,"enrollment":30,"conditions":820,"interventions":822},"NCT00467116","PhI Study of Erbitux & Gemcitabine w\u002FRadiation Therapy for Locally Adv. Pancreas Ca",[88],"2007-08","2005-10",[821],"Pancreatic Cancer",[792,823],"gemcitabine hydrochloride",{"trials":825,"activeCount":99},[826],{"nctId":827,"briefTitle":828,"status":207,"phases":829,"primaryCompletion":341,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":834},"NCT00466505","Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery",[89],"2008-11","2005-05",17,[29],[792,835,288],"celecoxib",{"trials":837,"activeCount":99},[],{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[],{"intervention":843,"totalTrials":257,"cells":844},"Panitumumab",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":859,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":95,"soonestReadout":853},[849],{"nctId":850,"briefTitle":851,"status":109,"phases":852,"primaryCompletion":853,"completion":854,"start":855,"enrollment":594,"conditions":856,"interventions":858},"NCT05901545","Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer",[88],"2028-11-30","2029-11-30","2023-08-22",[809,857],"Recurrent Head and Neck Squamous Cell Carcinoma",[843],{"trials":860,"activeCount":99},[861],{"nctId":862,"briefTitle":863,"status":207,"phases":864,"primaryCompletion":865,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":873},"NCT03263429","Novel PET\u002FCT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer",[88,89],"2023-08-15","2023-12-21","2017-08-23",29,[29,870,871,872],"Metastatic Colorectal Cancer","RAS Wild Type Colorectal Cancer","Refractory Colorectal Cancer",[874,843,875],"Glutaminase Inhibitor CB-839","Irinotecan Hydrochloride",{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":99},[],{"trials":881,"activeCount":99},[],{"intervention":41,"totalTrials":95,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":95,"soonestReadout":40},[888],{"nctId":38,"briefTitle":39,"status":453,"phases":889,"primaryCompletion":40,"completion":717,"start":718,"enrollment":719,"conditions":890,"interventions":891},[88],[710,721,722,723,724,358],[41,687],{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":99},[],{"intervention":813,"totalTrials":95,"cells":901},{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":95,"soonestReadout":803},[906],{"nctId":800,"briefTitle":801,"status":109,"phases":907,"primaryCompletion":803,"completion":804,"start":805,"enrollment":235,"conditions":908,"interventions":909},[88],[807,808,809,810],[812,813],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[],{"intervention":919,"totalTrials":95,"cells":920},"Panitumumab-IRDye800",{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":940},{"trials":922,"activeCount":99},[],{"trials":924,"activeCount":95,"soonestReadout":929},[925],{"nctId":926,"briefTitle":927,"status":109,"phases":928,"primaryCompletion":929,"completion":930,"start":931,"enrollment":187,"conditions":932,"interventions":933},"NCT05945875","Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer",[88],"2027-12-31","2028-12-31","2023-10-03",[809,857],[919],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":99},[],{"trials":939,"activeCount":99},[],{"trials":941,"activeCount":99},[],{"intervention":46,"totalTrials":95,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":959,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":945,"activeCount":99},[],{"trials":947,"activeCount":95,"soonestReadout":45},[948],{"nctId":43,"briefTitle":44,"status":453,"phases":949,"primaryCompletion":45,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":958},[88],"2025-12","2022-11-09",15,[954,955,956,957],"Gastric Cancer","Metaplasia","Stage I Gastric Cancer","Initial-onset Gastric Cancer",[46],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"intervention":76,"totalTrials":95,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":95,"soonestReadout":75},[973],{"nctId":73,"briefTitle":74,"status":109,"phases":974,"primaryCompletion":75,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":984},[88],"2027-10-01","2024-08-14",60,[979,980,981,982,983],"Relapsed Myelodysplastic Syndrome","Refractory Myelodysplastic Syndrome","Acute Myeloid Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[76,985],"Venetoclax",{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":99},[],{"trials":993,"activeCount":99},[],{"intervention":985,"totalTrials":95,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":95,"soonestReadout":75},[1000],{"nctId":73,"briefTitle":74,"status":109,"phases":1001,"primaryCompletion":75,"completion":975,"start":976,"enrollment":977,"conditions":1002,"interventions":1003},[88],[979,980,981,982,983],[76,985],{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"intervention":201,"totalTrials":95,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":95,"soonestReadout":184},[1018],{"nctId":180,"briefTitle":181,"status":182,"phases":1019,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":1020,"interventions":1021},[88],[189,190,191,192,193,194,195,196,197,198,199],[201,144],{"trials":1023,"activeCount":99},[],{"trials":1025,"activeCount":99},[],{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[],{"intervention":1031,"totalTrials":95,"cells":1032},"Panitumumab IRDye 800",{"EARLY_PHASE1":1033,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1054},{"trials":1034,"activeCount":95,"soonestReadout":1039},[1035],{"nctId":1036,"briefTitle":1037,"status":109,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":293,"conditions":1042,"interventions":1045},"NCT06819228","Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer",[87],"2028-03","2029-03","2025-04-17",[1043,1044,807],"HNSCC","HNSCC,Larynx, Pharynx and Oral Cavity",[1031],{"trials":1047,"activeCount":99},[],{"trials":1049,"activeCount":99},[],{"trials":1051,"activeCount":99},[],{"trials":1053,"activeCount":99},[],{"trials":1055,"activeCount":99},[],{"intervention":1057,"totalTrials":95,"cells":1058},"[68Ga]Ga-ABY-025",{"EARLY_PHASE1":1059,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1081,"NA":1083},{"trials":1060,"activeCount":95,"soonestReadout":1065},[1061],{"nctId":1062,"briefTitle":1063,"status":109,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":594,"conditions":1068,"interventions":1074},"NCT06828588","Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy",[87],"2027-12","2029-12","2026-04-16",[1069,1070,1071,1072,1073],"Locally Advanced Cancer","Metastatic Cancer","HER2","HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma","HER 2 Low-expressing Breast Cancer",[1057],{"trials":1076,"activeCount":99},[],{"trials":1078,"activeCount":99},[],{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[],{"intervention":66,"totalTrials":95,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1088,"activeCount":95,"soonestReadout":65},[1089],{"nctId":63,"briefTitle":64,"status":109,"phases":1090,"primaryCompletion":65,"completion":1091,"start":1092,"enrollment":761,"conditions":1093,"interventions":1095},[87],"2029-05-31","2023-05-17",[809,1094],"Brain Metastases",[66],{"trials":1097,"activeCount":99},[],{"trials":1099,"activeCount":99},[],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"intervention":287,"totalTrials":748,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"trials":1113,"activeCount":99},[1114,1123,1127,1135],{"nctId":1115,"briefTitle":1116,"status":167,"phases":1117,"primaryCompletion":697,"completion":1118,"start":367,"enrollment":1119,"conditions":1120,"interventions":1121},"NCT00343512","Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer",[89],"2011-03",34,[15],[1122,287],"docetaxel",{"nctId":273,"briefTitle":274,"status":207,"phases":1124,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":1125,"interventions":1126},[89],[18],[282,283,284,285,286,287,288],{"nctId":1128,"briefTitle":1129,"status":207,"phases":1130,"primaryCompletion":278,"completion":278,"start":1131,"enrollment":344,"conditions":1132,"interventions":1133},"NCT00633750","Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery",[89],"2002-08",[15],[284,1134,287],"TUNEL assay",{"nctId":1136,"briefTitle":1137,"status":207,"phases":1138,"primaryCompletion":1139,"completion":1140,"start":818,"enrollment":1141,"conditions":1142,"interventions":1143},"NCT00514020","Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer",[89],"2011-01","2011-02",33,[954],[1144,1145,1146,286,1147,287],"fluorouracil","leucovorin calcium","oxaliplatin","polymorphism analysis",{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":95,"soonestReadout":1186},[1154,1162,1170,1182,1191,1199,1208],{"nctId":1155,"briefTitle":1156,"status":207,"phases":1157,"primaryCompletion":771,"completion":341,"start":1158,"enrollment":33,"conditions":1159,"interventions":1161},"NCT00900523","Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer",[],"2006-11",[1160],"Ovarian Cancer",[287],{"nctId":1163,"briefTitle":1164,"status":207,"phases":1165,"primaryCompletion":697,"completion":697,"start":1166,"enrollment":224,"conditions":1167,"interventions":1168},"NCT00899340","Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx",[],"2006-05",[21],[286,1169,287],"microarray analysis",{"nctId":1171,"briefTitle":1172,"status":207,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT00897650","Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer",[],"2016-07","2017-07","2005-12",204,[18],[1180,1181],"DNA\u002FRNA sequencing and expression levels","Protein expression analysis",{"nctId":1183,"briefTitle":1184,"status":109,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1190},"NCT00897117","Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer",[],"2031-05-31","2001-05",4000,[18],[286,1169,287],{"nctId":1192,"briefTitle":1193,"status":207,"phases":1194,"primaryCompletion":830,"completion":830,"start":1195,"enrollment":1141,"conditions":1196,"interventions":1197},"NCT00483457","Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients",[],"2006-02",[27],[1198,287],"enzyme inhibitor therapy",{"nctId":1200,"briefTitle":1201,"status":167,"phases":1202,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":25,"conditions":1206,"interventions":1207},"NCT00608595","Celecoxib in Treating Patients With Early-Stage Rectal Cancer",[92],"2004-05","2008-04","2002-07",[29],[835,286,287],{"nctId":1209,"briefTitle":1210,"status":167,"phases":1211,"primaryCompletion":1212,"completion":779,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1216},"NCT00898209","Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)",[],"2009-02","2003-04",564,[18],[287,288],{"intervention":286,"totalTrials":688,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1220,"activeCount":99},[],{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[1225,1229,1239],{"nctId":273,"briefTitle":274,"status":207,"phases":1226,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":1227,"interventions":1228},[89],[18],[282,283,284,285,286,287,288],{"nctId":1230,"briefTitle":1231,"status":207,"phases":1232,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1119,"conditions":1236,"interventions":1238},"NCT00466687","Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma",[89],"2008-08","2008-09","2004-09",[1237],"Melanoma",[282,284,764,286],{"nctId":1136,"briefTitle":1137,"status":207,"phases":1240,"primaryCompletion":1139,"completion":1140,"start":818,"enrollment":1141,"conditions":1241,"interventions":1242},[89],[954],[1144,1145,1146,286,1147,287],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":95,"soonestReadout":1186},[1249,1260,1264,1280,1284],{"nctId":1250,"briefTitle":1251,"status":207,"phases":1252,"primaryCompletion":1204,"completion":1204,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1256},"NCT00898664","DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer",[],"2006-06",74,[21],[1257,286,1258,1259],"cytogenetic analysis","mutation analysis","polymerase chain reaction",{"nctId":1163,"briefTitle":1164,"status":207,"phases":1261,"primaryCompletion":697,"completion":697,"start":1166,"enrollment":224,"conditions":1262,"interventions":1263},[],[21],[286,1169,287],{"nctId":1265,"briefTitle":1266,"status":207,"phases":1267,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1279},"NCT00900406","Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant",[],"2010-03","2007-01",190,[15,1272,1273,1274,35,24,1275,32,1276,1277,1160,1278],"Chronic Myeloproliferative Disorders","Gestational Trophoblastic Tumor","Graft Versus Host Disease","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasms","Neuroblastoma","Testicular Germ Cell Tumor",[286,1169,1147,288],{"nctId":1183,"briefTitle":1184,"status":109,"phases":1281,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1282,"interventions":1283},[],[18],[286,1169,287],{"nctId":1200,"briefTitle":1201,"status":167,"phases":1285,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":25,"conditions":1286,"interventions":1287},[92],[29],[835,286,287],{"intervention":1169,"totalTrials":9,"cells":1289},{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1291,"activeCount":99},[],{"trials":1293,"activeCount":99},[],{"trials":1295,"activeCount":99},[],{"trials":1297,"activeCount":99},[],{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":95,"soonestReadout":1186},[1302,1306,1310,1318],{"nctId":1163,"briefTitle":1164,"status":207,"phases":1303,"primaryCompletion":697,"completion":697,"start":1166,"enrollment":224,"conditions":1304,"interventions":1305},[],[21],[286,1169,287],{"nctId":1265,"briefTitle":1266,"status":207,"phases":1307,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":1308,"interventions":1309},[],[15,1272,1273,1274,35,24,1275,32,1276,1277,1160,1278],[286,1169,1147,288],{"nctId":1311,"briefTitle":1312,"status":207,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":868,"conditions":1316,"interventions":1317},"NCT00897052","Gene Expression Profiles in Predicting Survival of Patients With Head and Neck Cancer",[],"2007-12","2005-02",[21],[1169],{"nctId":1183,"briefTitle":1184,"status":109,"phases":1319,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1320,"interventions":1321},[],[18],[286,1169,287],{"intervention":71,"totalTrials":257,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1325,"activeCount":99},[],{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"trials":1331,"activeCount":99},[],{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":95,"soonestReadout":70},[1336,1345],{"nctId":1337,"briefTitle":1338,"status":153,"phases":1339,"primaryCompletion":1340,"completion":1340,"start":771,"enrollment":99,"conditions":1341,"interventions":1343},"NCT00899002","Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer",[],"2009-05",[1342],"Liver Cancer",[71,1344,1258,1259,288],"molecular genetic technique",{"nctId":68,"briefTitle":69,"status":109,"phases":1346,"primaryCompletion":70,"completion":70,"start":343,"enrollment":1188,"conditions":1347,"interventions":1348},[],[18],[71,1349,1350],"gene expression microarray analysis","proteomic profiling analysis",{"intervention":1349,"totalTrials":95,"cells":1352},{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":95,"soonestReadout":70},[1365],{"nctId":68,"briefTitle":69,"status":109,"phases":1366,"primaryCompletion":70,"completion":70,"start":343,"enrollment":1188,"conditions":1367,"interventions":1368},[],[18],[71,1349,1350],{"intervention":1350,"totalTrials":95,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[],{"trials":1382,"activeCount":95,"soonestReadout":70},[1383],{"nctId":68,"briefTitle":69,"status":109,"phases":1384,"primaryCompletion":70,"completion":70,"start":343,"enrollment":1188,"conditions":1385,"interventions":1386},[],[18],[71,1349,1350],{"intervention":1388,"totalTrials":95,"cells":1389},"Axicabtagene Ciloleucel",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1412},{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[],{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[1400],{"nctId":1401,"briefTitle":1402,"status":207,"phases":1403,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":235,"conditions":1406,"interventions":1409},"NCT05108805","Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting",[91],"2023-12-08","2021-12-02",[1407,1408],"Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",[1388,1410,1411],"Cyclophosphamide","Fludarabine",{"trials":1413,"activeCount":99},[],{"intervention":1415,"totalTrials":95,"cells":1416},"Nicotine Replacement Therapy",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1437,"NA":1439},{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":99},[],{"trials":1424,"activeCount":99},[1425],{"nctId":1426,"briefTitle":1427,"status":207,"phases":1428,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":1432,"conditions":1433,"interventions":1435},"NCT04590404","Metabolism Informed Smoking Treatment: The MIST RCT",[90],"2024-05-20","2024-11-22","2020-11-17",606,[1434],"Smoking",[1415,1436],"Varenicline",{"trials":1438,"activeCount":99},[],{"trials":1440,"activeCount":99},[],{"intervention":1436,"totalTrials":95,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1455,"NA":1457},{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[1451],{"nctId":1426,"briefTitle":1427,"status":207,"phases":1452,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":1432,"conditions":1453,"interventions":1454},[90],[1434],[1415,1436],{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":99},[],{"intervention":1460,"totalTrials":95,"cells":1461},"cyclosporine ophthalmic emulsion",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1468,"PHASE4":1478,"NA":1480},{"trials":1463,"activeCount":99},[],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[1470],{"nctId":1471,"briefTitle":1472,"status":207,"phases":1473,"primaryCompletion":40,"completion":731,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT00755040","Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder",[90],"2008-10",164,[1272,1274,35,24,1275,32,1276],[1460],{"trials":1479,"activeCount":99},[],{"trials":1481,"activeCount":99},[],{"intervention":1483,"totalTrials":95,"cells":1484},"Gabapentin",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1511,"NA":1513},{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":99},[],{"trials":1492,"activeCount":99},[1493],{"nctId":1494,"briefTitle":1495,"status":207,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1505},"NCT02480114","Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy",[90],"2019-09","2020-01","2015-07",79,[1502,1503,1504],"Malignant Head and Neck Neoplasm","Mucositis","Radiation-Induced Disorder",[1483,1506,1507,1508,1509,1510],"Oxycodone\u002FAcetaminophen","Hydrocodone\u002FAcetaminophen","Fentanyl","Ibuprofen","Magic Mouthwash",{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"intervention":1506,"totalTrials":95,"cells":1516},{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1529,"NA":1531},{"trials":1518,"activeCount":99},[],{"trials":1520,"activeCount":99},[],{"trials":1522,"activeCount":99},[],{"trials":1524,"activeCount":99},[1525],{"nctId":1494,"briefTitle":1495,"status":207,"phases":1526,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1527,"interventions":1528},[90],[1502,1503,1504],[1483,1506,1507,1508,1509,1510],{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"intervention":1507,"totalTrials":95,"cells":1534},{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1547,"NA":1549},{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[1543],{"nctId":1494,"briefTitle":1495,"status":207,"phases":1544,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1545,"interventions":1546},[90],[1502,1503,1504],[1483,1506,1507,1508,1509,1510],{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[],{"intervention":1508,"totalTrials":95,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1565,"NA":1567},{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[1561],{"nctId":1494,"briefTitle":1495,"status":207,"phases":1562,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1563,"interventions":1564},[90],[1502,1503,1504],[1483,1506,1507,1508,1509,1510],{"trials":1566,"activeCount":99},[],{"trials":1568,"activeCount":99},[],{"intervention":1509,"totalTrials":95,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1583,"NA":1585},{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[1579],{"nctId":1494,"briefTitle":1495,"status":207,"phases":1580,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1581,"interventions":1582},[90],[1502,1503,1504],[1483,1506,1507,1508,1509,1510],{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[],{"intervention":1510,"totalTrials":95,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1601,"NA":1603},{"trials":1590,"activeCount":99},[],{"trials":1592,"activeCount":99},[],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[1597],{"nctId":1494,"briefTitle":1495,"status":207,"phases":1598,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1599,"interventions":1600},[90],[1502,1503,1504],[1483,1506,1507,1508,1509,1510],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"intervention":284,"totalTrials":688,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1625,"PHASE3":1659,"PHASE4":1661,"NA":1663},{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[1611],{"nctId":1612,"briefTitle":1613,"status":207,"phases":1614,"primaryCompletion":1615,"completion":1616,"start":1617,"enrollment":1618,"conditions":1619,"interventions":1624},"NCT00987766","Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",[88],"2013-07","2016-10","2009-11",28,[1620,1621,1342,821,1622,1623],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Periampullary Adenocarcinoma","Small Intestine Cancer",[284,823,1146],{"trials":1626,"activeCount":99},[1627,1631,1635,1643,1647,1651,1655],{"nctId":273,"briefTitle":274,"status":207,"phases":1628,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":1629,"interventions":1630},[89],[18],[282,283,284,285,286,287,288],{"nctId":300,"briefTitle":301,"status":153,"phases":1632,"primaryCompletion":303,"completion":303,"start":304,"enrollment":99,"conditions":1633,"interventions":1634},[89],[306,307],[309,283,310,284],{"nctId":1636,"briefTitle":1637,"status":207,"phases":1638,"primaryCompletion":278,"completion":1639,"start":1205,"enrollment":1640,"conditions":1641,"interventions":1642},"NCT00416650","Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer",[89],"2013-03",16,[18],[284],{"nctId":1128,"briefTitle":1129,"status":207,"phases":1644,"primaryCompletion":278,"completion":278,"start":1131,"enrollment":344,"conditions":1645,"interventions":1646},[89],[15],[284,1134,287],{"nctId":1230,"briefTitle":1231,"status":207,"phases":1648,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1119,"conditions":1649,"interventions":1650},[89],[1237],[282,284,764,286],{"nctId":756,"briefTitle":757,"status":167,"phases":1652,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":1653,"interventions":1654},[89],[15],[284,687,764],{"nctId":776,"briefTitle":777,"status":153,"phases":1656,"primaryCompletion":779,"completion":779,"start":780,"enrollment":99,"conditions":1657,"interventions":1658},[89],[15],[783,284,784,687],{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"intervention":310,"totalTrials":33,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1679,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[1671],{"nctId":1672,"briefTitle":1673,"status":207,"phases":1674,"primaryCompletion":780,"completion":770,"start":1675,"enrollment":293,"conditions":1676,"interventions":1677},"NCT00680758","Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer",[88],"2008-05",[15],[310,1678,285],"everolimus",{"trials":1680,"activeCount":99},[1681,1685,1689,1697,1709,1718],{"nctId":300,"briefTitle":301,"status":153,"phases":1682,"primaryCompletion":303,"completion":303,"start":304,"enrollment":99,"conditions":1683,"interventions":1684},[89],[306,307],[309,283,310,284],{"nctId":312,"briefTitle":313,"status":167,"phases":1686,"primaryCompletion":315,"completion":315,"start":316,"enrollment":95,"conditions":1687,"interventions":1688},[89],[318,319,320,239],[322,56,298,242],{"nctId":1690,"briefTitle":1673,"status":207,"phases":1691,"primaryCompletion":1692,"completion":1693,"start":769,"enrollment":1694,"conditions":1695,"interventions":1696},"NCT01031446",[88,89],"2011-12","2017-08",55,[15],[310,1678,285],{"nctId":1698,"briefTitle":1699,"status":167,"phases":1700,"primaryCompletion":40,"completion":1701,"start":1702,"enrollment":748,"conditions":1703,"interventions":1707},"NCT01918306","GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer",[88,89],"2015-04","2013-09",[1704,1705,357,724,358,1706],"Estrogen Receptor Negative Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Triple-negative Breast Cancer",[310,1708],"GDC -0941",{"nctId":1710,"briefTitle":1711,"status":207,"phases":1712,"primaryCompletion":1713,"completion":341,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1717},"NCT00639769","Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[89],"2007-05","2002-02",41,[21],[310,347],{"nctId":1719,"briefTitle":1720,"status":207,"phases":1721,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1727},"NCT00930930","Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer",[89],"2013-10","2014-10","2009-06",145,[15],[310,1678,285],{"trials":1729,"activeCount":99},[],{"trials":1731,"activeCount":99},[],{"trials":1733,"activeCount":99},[],{"intervention":285,"totalTrials":113,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1768,"PHASE3":1782,"PHASE4":1784,"NA":1786},{"trials":1737,"activeCount":99},[],{"trials":1739,"activeCount":99},[1740,1755,1764],{"nctId":1741,"briefTitle":1742,"status":207,"phases":1743,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":868,"conditions":1747,"interventions":1752},"NCT02672475","Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer",[88],"2021-04","2023-08","2016-03",[1748,410,1749,1750,358,1751],"Estrogen Receptor Negative","Progesterone Receptor Negative","Recurrent Breast Carcinoma","Triple-Negative Breast Carcinoma",[1753,1754],"Galunisertib","Paclitaxel",{"nctId":1756,"briefTitle":1757,"status":207,"phases":1758,"primaryCompletion":1759,"completion":1759,"start":1760,"enrollment":113,"conditions":1761,"interventions":1762},"NCT00002519","Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer",[88],"2000-01","1997-01",[18],[1763,285],"chemotherapy",{"nctId":1672,"briefTitle":1673,"status":207,"phases":1765,"primaryCompletion":780,"completion":770,"start":1675,"enrollment":293,"conditions":1766,"interventions":1767},[88],[15],[310,1678,285],{"trials":1769,"activeCount":99},[1770,1774,1778],{"nctId":273,"briefTitle":274,"status":207,"phases":1771,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":1772,"interventions":1773},[89],[18],[282,283,284,285,286,287,288],{"nctId":1690,"briefTitle":1673,"status":207,"phases":1775,"primaryCompletion":1692,"completion":1693,"start":769,"enrollment":1694,"conditions":1776,"interventions":1777},[88,89],[15],[310,1678,285],{"nctId":1719,"briefTitle":1720,"status":207,"phases":1779,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":1780,"interventions":1781},[89],[15],[310,1678,285],{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"intervention":1122,"totalTrials":439,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1791,"activeCount":99},[],{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[1796,1804,1808,1816,1825],{"nctId":1797,"briefTitle":1798,"status":167,"phases":1799,"primaryCompletion":277,"completion":1800,"start":278,"enrollment":1801,"conditions":1802,"interventions":1803},"NCT00520845","Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer",[89],"2014-01",23,[18],[835,371,309],{"nctId":1115,"briefTitle":1116,"status":167,"phases":1805,"primaryCompletion":697,"completion":1118,"start":367,"enrollment":1119,"conditions":1806,"interventions":1807},[89],[15],[1122,287],{"nctId":1809,"briefTitle":1810,"status":207,"phases":1811,"primaryCompletion":1724,"completion":1724,"start":1812,"enrollment":235,"conditions":1813,"interventions":1814},"NCT00425750","Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[89],"2005-08",[21],[1815,1122],"bortezomib",{"nctId":1817,"briefTitle":1818,"status":207,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":719,"conditions":1822,"interventions":1823},"NCT00006104","Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer",[89],"2003-07","1998-09",[15],[1824,1122],"trastuzumab",{"nctId":363,"briefTitle":364,"status":167,"phases":1826,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":1827,"interventions":1828},[89],[18],[56,371],{"trials":1830,"activeCount":99},[],{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[],{"intervention":309,"totalTrials":9,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1847,"PHASE3":1866,"PHASE4":1868,"NA":1870},{"trials":1838,"activeCount":99},[],{"trials":1840,"activeCount":99},[1841],{"nctId":1842,"briefTitle":1843,"status":207,"phases":1844,"primaryCompletion":1713,"completion":332,"start":1203,"enrollment":235,"conditions":1845,"interventions":1846},"NCT00470405","Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma",[88],[24,27],[1146,309],{"trials":1848,"activeCount":99},[1849,1853,1857],{"nctId":1797,"briefTitle":1798,"status":167,"phases":1850,"primaryCompletion":277,"completion":1800,"start":278,"enrollment":1801,"conditions":1851,"interventions":1852},[89],[18],[835,371,309],{"nctId":300,"briefTitle":301,"status":153,"phases":1854,"primaryCompletion":303,"completion":303,"start":304,"enrollment":99,"conditions":1855,"interventions":1856},[89],[306,307],[309,283,310,284],{"nctId":1858,"briefTitle":1859,"status":207,"phases":1860,"primaryCompletion":1724,"completion":1861,"start":1862,"enrollment":1863,"conditions":1864,"interventions":1865},"NCT00503997","Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer",[89],"2010-06","2006-12",42,[21],[1146,309],{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[],{"intervention":754,"totalTrials":9,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1886,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[1878],{"nctId":1879,"briefTitle":1880,"status":153,"phases":1881,"enrollment":99,"conditions":1882,"interventions":1883},"NCT01240928","MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer",[88],[735],[1884,1885,754],"MSK-2206","Exemestane",{"trials":1887,"activeCount":99},[1888,1892,1900],{"nctId":743,"briefTitle":744,"status":167,"phases":1889,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":1890,"interventions":1891},[89],[750],[752,753,712,754],{"nctId":1893,"briefTitle":1894,"status":153,"phases":1895,"primaryCompletion":1896,"completion":730,"start":1140,"enrollment":99,"conditions":1897,"interventions":1898},"NCT01240941","Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer",[89],"2012-06",[735],[1899,1885,754],"MK-2206",{"nctId":776,"briefTitle":777,"status":153,"phases":1901,"primaryCompletion":779,"completion":779,"start":780,"enrollment":99,"conditions":1902,"interventions":1903},[89],[15],[783,284,784,687],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"intervention":1146,"totalTrials":9,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1924,"PHASE3":1934,"PHASE4":1936,"NA":1938},{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[1916,1920],{"nctId":1612,"briefTitle":1613,"status":207,"phases":1917,"primaryCompletion":1615,"completion":1616,"start":1617,"enrollment":1618,"conditions":1918,"interventions":1919},[88],[1620,1621,1342,821,1622,1623],[284,823,1146],{"nctId":1842,"briefTitle":1843,"status":207,"phases":1921,"primaryCompletion":1713,"completion":332,"start":1203,"enrollment":235,"conditions":1922,"interventions":1923},[88],[24,27],[1146,309],{"trials":1925,"activeCount":99},[1926,1930],{"nctId":1858,"briefTitle":1859,"status":207,"phases":1927,"primaryCompletion":1724,"completion":1861,"start":1862,"enrollment":1863,"conditions":1928,"interventions":1929},[89],[21],[1146,309],{"nctId":1136,"briefTitle":1137,"status":207,"phases":1931,"primaryCompletion":1139,"completion":1140,"start":818,"enrollment":1141,"conditions":1932,"interventions":1933},[89],[954],[1144,1145,1146,286,1147,287],{"trials":1935,"activeCount":99},[],{"trials":1937,"activeCount":99},[],{"trials":1939,"activeCount":99},[],{"intervention":347,"totalTrials":793,"cells":1941},{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1943,"activeCount":99},[],{"trials":1945,"activeCount":99},[],{"trials":1947,"activeCount":99},[1948,1952,1956],{"nctId":862,"briefTitle":863,"status":207,"phases":1949,"primaryCompletion":865,"completion":866,"start":867,"enrollment":868,"conditions":1950,"interventions":1951},[88,89],[29,870,871,872],[874,843,875],{"nctId":1710,"briefTitle":1711,"status":207,"phases":1953,"primaryCompletion":1713,"completion":341,"start":1714,"enrollment":1715,"conditions":1954,"interventions":1955},[89],[21],[310,347],{"nctId":338,"briefTitle":339,"status":207,"phases":1957,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":1958,"interventions":1959},[89],[18],[56,347],{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[],{"intervention":282,"totalTrials":793,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1984,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1969,"activeCount":99},[],{"trials":1971,"activeCount":99},[1972],{"nctId":1973,"briefTitle":1974,"status":207,"phases":1975,"primaryCompletion":1976,"completion":1977,"start":1615,"enrollment":1978,"conditions":1979,"interventions":1981},"NCT01891747","A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma",[88],"2015-06","2022-01-31",14,[1980],"Malignant Glioma",[1982,1983],"Bevacizumab","Temozolomide",{"trials":1985,"activeCount":99},[1986,1990],{"nctId":273,"briefTitle":274,"status":207,"phases":1987,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":1988,"interventions":1989},[89],[18],[282,283,284,285,286,287,288],{"nctId":1230,"briefTitle":1231,"status":207,"phases":1991,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1119,"conditions":1992,"interventions":1993},[89],[1237],[282,284,764,286],{"trials":1995,"activeCount":99},[],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"intervention":1678,"totalTrials":793,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2010,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[2006],{"nctId":1672,"briefTitle":1673,"status":207,"phases":2007,"primaryCompletion":780,"completion":770,"start":1675,"enrollment":293,"conditions":2008,"interventions":2009},[88],[15],[310,1678,285],{"trials":2011,"activeCount":99},[2012,2016],{"nctId":1690,"briefTitle":1673,"status":207,"phases":2013,"primaryCompletion":1692,"completion":1693,"start":769,"enrollment":1694,"conditions":2014,"interventions":2015},[88,89],[15],[310,1678,285],{"nctId":1719,"briefTitle":1720,"status":207,"phases":2017,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":2018,"interventions":2019},[89],[15],[310,1678,285],{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"intervention":178,"totalTrials":793,"cells":2027},{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2036,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2029,"activeCount":99},[],{"trials":2031,"activeCount":99},[2032],{"nctId":165,"briefTitle":166,"status":167,"phases":2033,"primaryCompletion":169,"completion":169,"start":170,"enrollment":113,"conditions":2034,"interventions":2035},[88],[172,173,174,175],[144,177,178],{"trials":2037,"activeCount":99},[2038,2046],{"nctId":2039,"briefTitle":2040,"status":207,"phases":2041,"primaryCompletion":2042,"completion":2042,"start":1474,"enrollment":2043,"conditions":2044,"interventions":2045},"NCT00765245","Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",[89],"2014-11",44,[24],[178,178,177],{"nctId":2047,"briefTitle":2048,"status":207,"phases":2049,"primaryCompletion":2050,"completion":2051,"start":732,"enrollment":2052,"conditions":2053,"interventions":2055},"NCT01215344","First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade",[89],"2015-11","2018-03",36,[2054],"Multiple Myeloma",[2056,178,2057,2058,2059,2060,2057],"VELCADE","Dexamethasone","DVT prophylaxis","Bisphosphonates","Liposomal doxorubicin",{"trials":2062,"activeCount":99},[],{"trials":2064,"activeCount":99},[],{"trials":2066,"activeCount":99},[],{"intervention":1983,"totalTrials":793,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2117,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[2073,2113],{"nctId":2074,"briefTitle":2075,"status":153,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":99,"conditions":2080,"interventions":2110},"NCT02831179","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",[88],"2019-02","2020-02","2017-12",[2081,2082,2083,2084,2085,2086,2087,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,2107,2108,2109],"Functional Pancreatic Neuroendocrine Tumor","Malignant Somatostatinoma","Merkel Cell Carcinoma","Metastatic Adrenal Gland Pheochromocytoma","Metastatic Carcinoid Tumor","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2A","Multiple Endocrine Neoplasia Type 2B","Neuroendocrine Neoplasm","Non-Functional Pancreatic Neuroendocrine Tumor","Pancreatic Glucagonoma","Pancreatic Insulinoma","Recurrent Adrenal Cortex Carcinoma","Recurrent Adrenal Gland Pheochromocytoma","Recurrent Merkel Cell Carcinoma","Somatostatin-Producing Neuroendocrine Tumor","Stage III Adrenal Cortex Carcinoma","Stage III Thyroid Gland Medullary Carcinoma","Stage IIIA Merkel Cell Carcinoma","Stage IIIB Merkel Cell Carcinoma","Stage IV Adrenal Cortex Carcinoma","Stage IV Merkel Cell Carcinoma","Stage IVA Thyroid Gland Medullary Carcinoma","Stage IVB Thyroid Gland Medullary Carcinoma","Stage IVC Thyroid Gland Medullary Carcinoma","Thymic Carcinoid Tumor","VIP-Producing Neuroendocrine Tumor","Well Differentiated Adrenal Cortex Carcinoma","Zollinger Ellison Syndrome",[2111,1983,2112],"Capecitabine","Veliparib",{"nctId":1973,"briefTitle":1974,"status":207,"phases":2114,"primaryCompletion":1976,"completion":1977,"start":1615,"enrollment":1978,"conditions":2115,"interventions":2116},[88],[1980],[1982,1983],{"trials":2118,"activeCount":99},[2119],{"nctId":2120,"briefTitle":2121,"status":167,"phases":2122,"primaryCompletion":2123,"completion":697,"start":2124,"enrollment":2125,"conditions":2126,"interventions":2128},"NCT00512798","Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma",[88,89],"2006-07","2003-06",47,[2127,1237,27],"Brain and Central Nervous System Tumors",[2129,2130,2129,1983],"PS-341","temozolomide",{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"intervention":1144,"totalTrials":257,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2156,"PHASE4":2158,"NA":2160},{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[2145,2152],{"nctId":2146,"briefTitle":2147,"status":207,"phases":2148,"primaryCompletion":2149,"completion":697,"start":1205,"enrollment":19,"conditions":2150,"interventions":2151},"NCT00336960","Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery",[89],"2004-11",[29],[835,1144],{"nctId":1136,"briefTitle":1137,"status":207,"phases":2153,"primaryCompletion":1139,"completion":1140,"start":818,"enrollment":1141,"conditions":2154,"interventions":2155},[89],[954],[1144,1145,1146,286,1147,287],{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"intervention":2163,"totalTrials":257,"cells":2164},"trametinib",{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2197,"PHASE4":2199,"NA":2201},{"trials":2166,"activeCount":99},[],{"trials":2168,"activeCount":99},[],{"trials":2170,"activeCount":99},[2171,2187],{"nctId":2172,"briefTitle":2173,"status":167,"phases":2174,"primaryCompletion":2175,"completion":1701,"start":2176,"enrollment":333,"conditions":2177,"interventions":2185},"NCT01701037","Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery",[89],"2015-02","2013-01",[2178,2179,2180,2181,2182,2183,2184],"Recurrent Melanoma","Stage IIB Melanoma (Locally Advanced)","Stage IIC Melanoma (Locally Advanced)","Stage IIIA Melanoma","Stage IIIB Melanoma","Stage IIIC Melanoma","Stage IV Melanoma (Limited, Resectable)",[2186,2163],"dabrafenib",{"nctId":2188,"briefTitle":2189,"status":207,"phases":2190,"primaryCompletion":2191,"completion":2192,"start":2193,"enrollment":30,"conditions":2194,"interventions":2196},"NCT02296112","Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations",[89],"2018-08","2021-04-16","2015-01",[2178,2182,2183,2195],"Stage IV Melanoma",[2163],{"trials":2198,"activeCount":99},[],{"trials":2200,"activeCount":99},[],{"trials":2202,"activeCount":99},[],{"intervention":2204,"totalTrials":257,"cells":2205},"Trivalent Influenza Vaccine",{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2238,"PHASE4":2240,"NA":2242},{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[2212,2224],{"nctId":2213,"briefTitle":2214,"status":207,"phases":2215,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2219,"conditions":2220,"interventions":2222},"NCT03179761","High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients",[89],"2022-02-15","2024-10-01","2017-10-09",124,[2221],"Hematopoietic Cell Transplantation",[2223,2204],"Quadrivalent Inactivated Influenza Vaccine",{"nctId":2225,"briefTitle":2226,"status":207,"phases":2227,"primaryCompletion":2228,"completion":2229,"start":2230,"enrollment":2231,"conditions":2232,"interventions":2236},"NCT02860039","High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant",[89],"2021-12-01","2024-09","2016-09",170,[2233,2234,2235],"Hematopoietic Cell Transplantation Recipient","Malignant Neoplasm","Influenza",[2204,2237],"Quadrivalent Influenza Vaccine",{"trials":2239,"activeCount":99},[],{"trials":2241,"activeCount":99},[],{"trials":2243,"activeCount":99},[],{"intervention":753,"totalTrials":257,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2259,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[2250],{"nctId":2251,"briefTitle":2252,"status":207,"phases":2253,"primaryCompletion":2254,"completion":1212,"start":1176,"enrollment":1978,"conditions":2255,"interventions":2256},"NCT00574366","Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer",[88],"2009-01",[15],[2257,2258],"erlotinib","RAD001",{"trials":2260,"activeCount":99},[2261],{"nctId":743,"briefTitle":744,"status":167,"phases":2262,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":2263,"interventions":2264},[89],[750],[752,753,712,754],{"trials":2266,"activeCount":99},[],{"trials":2268,"activeCount":99},[],{"trials":2270,"activeCount":99},[],{"intervention":764,"totalTrials":257,"cells":2272},{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2287,"PHASE4":2289,"NA":2291},{"trials":2274,"activeCount":99},[],{"trials":2276,"activeCount":99},[],{"trials":2278,"activeCount":99},[2279,2283],{"nctId":1230,"briefTitle":1231,"status":207,"phases":2280,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1119,"conditions":2281,"interventions":2282},[89],[1237],[282,284,764,286],{"nctId":756,"briefTitle":757,"status":167,"phases":2284,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":2285,"interventions":2286},[89],[15],[284,687,764],{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":99},[],{"trials":2292,"activeCount":99},[],{"intervention":177,"totalTrials":257,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2303,"PHASE3":2309,"PHASE4":2311,"NA":2313},{"trials":2296,"activeCount":99},[],{"trials":2298,"activeCount":99},[2299],{"nctId":165,"briefTitle":166,"status":167,"phases":2300,"primaryCompletion":169,"completion":169,"start":170,"enrollment":113,"conditions":2301,"interventions":2302},[88],[172,173,174,175],[144,177,178],{"trials":2304,"activeCount":99},[2305],{"nctId":2039,"briefTitle":2040,"status":207,"phases":2306,"primaryCompletion":2042,"completion":2042,"start":1474,"enrollment":2043,"conditions":2307,"interventions":2308},[89],[24],[178,178,177],{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[],{"intervention":1885,"totalTrials":257,"cells":2316},{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2325,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2318,"activeCount":99},[],{"trials":2320,"activeCount":99},[2321],{"nctId":1879,"briefTitle":1880,"status":153,"phases":2322,"enrollment":99,"conditions":2323,"interventions":2324},[88],[735],[1884,1885,754],{"trials":2326,"activeCount":99},[2327],{"nctId":1893,"briefTitle":1894,"status":153,"phases":2328,"primaryCompletion":1896,"completion":730,"start":1140,"enrollment":99,"conditions":2329,"interventions":2330},[89],[735],[1899,1885,754],{"trials":2332,"activeCount":99},[],{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"intervention":2338,"totalTrials":95,"cells":2339},"Sorafenib",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[2346],{"nctId":2347,"briefTitle":2348,"status":207,"phases":2349,"primaryCompletion":2350,"completion":2351,"start":1474,"enrollment":8,"conditions":2352,"interventions":2353},"NCT00837876","Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery",[89],"2011-04","2012-11",[821],[2338,2354],"Erlotinb",{"trials":2356,"activeCount":99},[],{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[],{"intervention":2354,"totalTrials":95,"cells":2362},{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2373,"PHASE4":2375,"NA":2377},{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[2369],{"nctId":2347,"briefTitle":2348,"status":207,"phases":2370,"primaryCompletion":2350,"completion":2351,"start":1474,"enrollment":8,"conditions":2371,"interventions":2372},[89],[821],[2338,2354],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":99},[],{"trials":2378,"activeCount":99},[],{"intervention":2380,"totalTrials":95,"cells":2381},"Azacitidine Subcutaneous Injection or Intravenous",{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2400,"PHASE4":2402,"NA":2404},{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[2388],{"nctId":2389,"briefTitle":2390,"status":207,"phases":2391,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":2395,"conditions":2396,"interventions":2398},"NCT03238248","Pevonedistat and Azacitidine in MDS or MDS\u002FMPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors",[89],"2022-09-30","2023-11-27","2017-08-07",71,[32,2397],"Myeloproliferative Neoplasm",[2380,2399],"Pevonedistat",{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[],{"intervention":2399,"totalTrials":95,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2409,"activeCount":99},[],{"trials":2411,"activeCount":99},[],{"trials":2413,"activeCount":99},[2414],{"nctId":2389,"briefTitle":2390,"status":207,"phases":2415,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":2395,"conditions":2416,"interventions":2417},[89],[32,2397],[2380,2399],{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[],{"intervention":2425,"totalTrials":95,"cells":2426},"atrasentan hydrochloride",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[2433],{"nctId":2434,"briefTitle":2435,"status":167,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":952,"conditions":2439,"interventions":2442},"NCT00653328","Ph II Atrasentan + DOXIL in Recurrent Ovarian\u002FFallopian\u002FPeritoneal Serous Papillary Adenocarcinoma",[89],"2009-03","2003-05",[2440,1160,2441],"Fallopian Tube Cancer","Peritoneal Cavity Cancer",[2425,2443],"doxil",{"trials":2445,"activeCount":99},[],{"trials":2447,"activeCount":99},[],{"trials":2449,"activeCount":99},[],{"intervention":2443,"totalTrials":95,"cells":2451},{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2462,"PHASE4":2464,"NA":2466},{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[2458],{"nctId":2434,"briefTitle":2435,"status":167,"phases":2459,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":952,"conditions":2460,"interventions":2461},[89],[2440,1160,2441],[2425,2443],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[],{"trials":2467,"activeCount":99},[],{"intervention":2186,"totalTrials":95,"cells":2469},{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2480,"PHASE4":2482,"NA":2484},{"trials":2471,"activeCount":99},[],{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[2476],{"nctId":2172,"briefTitle":2173,"status":167,"phases":2477,"primaryCompletion":2175,"completion":1701,"start":2176,"enrollment":333,"conditions":2478,"interventions":2479},[89],[2178,2179,2180,2181,2182,2183,2184],[2186,2163],{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[],{"intervention":874,"totalTrials":95,"cells":2487},{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2489,"activeCount":99},[],{"trials":2491,"activeCount":99},[],{"trials":2493,"activeCount":99},[2494],{"nctId":862,"briefTitle":863,"status":207,"phases":2495,"primaryCompletion":865,"completion":866,"start":867,"enrollment":868,"conditions":2496,"interventions":2497},[88,89],[29,870,871,872],[874,843,875],{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"intervention":2223,"totalTrials":95,"cells":2505},{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2510,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[],{"trials":2511,"activeCount":99},[2512],{"nctId":2213,"briefTitle":2214,"status":207,"phases":2513,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2219,"conditions":2514,"interventions":2515},[89],[2221],[2223,2204],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[],{"intervention":2523,"totalTrials":95,"cells":2524},"Artificial Tears",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[2531],{"nctId":2532,"briefTitle":2533,"status":167,"phases":2534,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":30,"conditions":2537,"interventions":2540},"NCT04327999","Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System",[89],"2023-09-25","2020-10-05",[2538,2539],"Thyroid Carcinoma","Radioactive Iodine Level",[2523],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"intervention":2548,"totalTrials":95,"cells":2549},"bendamustine hydrochloride",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[2556],{"nctId":2557,"briefTitle":2558,"status":207,"phases":2559,"primaryCompletion":2560,"completion":2560,"start":2561,"enrollment":344,"conditions":2562,"interventions":2563},"NCT00984542","Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer",[89],"2012-09","2009-09",[18],[2548],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[],{"trials":2569,"activeCount":99},[],{"intervention":2571,"totalTrials":95,"cells":2572},"linifanib",{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2594,"PHASE4":2596,"NA":2598},{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[2579],{"nctId":2580,"briefTitle":2581,"status":167,"phases":2582,"primaryCompletion":2583,"completion":2584,"start":2585,"enrollment":594,"conditions":2586,"interventions":2593},"NCT01365910","Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer",[89],"2012-05","2013-06","2011-06",[2587,2588,2589,2590,2591,2592],"Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[2571],{"trials":2595,"activeCount":99},[],{"trials":2597,"activeCount":99},[],{"trials":2599,"activeCount":99},[],{"intervention":2601,"totalTrials":95,"cells":2602},"octreotide acetate",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2618,"PHASE4":2620,"NA":2622},{"trials":2604,"activeCount":99},[],{"trials":2606,"activeCount":99},[],{"trials":2608,"activeCount":99},[2609],{"nctId":2610,"briefTitle":2611,"status":167,"phases":2612,"primaryCompletion":2613,"completion":278,"start":343,"enrollment":25,"conditions":2614,"interventions":2617},"NCT00466856","Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors",[89],"2006-10",[21,2615,1070,2616],"Islet Cell Tumor","Pheochromocytoma",[2601],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[],{"trials":2623,"activeCount":99},[],{"intervention":219,"totalTrials":95,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2636,"PHASE4":2638,"NA":2640},{"trials":2627,"activeCount":99},[],{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[2632],{"nctId":205,"briefTitle":206,"status":207,"phases":2633,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2634,"interventions":2635},[88,89],[214,215,216,217],[219,144],{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"trials":2641,"activeCount":99},[],{"intervention":1815,"totalTrials":95,"cells":2643},{"EARLY_PHASE1":2644,"PHASE1":2646,"PHASE2":2648,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2645,"activeCount":99},[],{"trials":2647,"activeCount":99},[],{"trials":2649,"activeCount":99},[2650],{"nctId":1809,"briefTitle":1810,"status":207,"phases":2651,"primaryCompletion":1724,"completion":1724,"start":1812,"enrollment":235,"conditions":2652,"interventions":2653},[89],[21],[1815,1122],{"trials":2655,"activeCount":99},[],{"trials":2657,"activeCount":99},[],{"trials":2659,"activeCount":99},[],{"intervention":2237,"totalTrials":95,"cells":2661},{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2672,"PHASE4":2674,"NA":2676},{"trials":2663,"activeCount":99},[],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[2668],{"nctId":2225,"briefTitle":2226,"status":207,"phases":2669,"primaryCompletion":2228,"completion":2229,"start":2230,"enrollment":2231,"conditions":2670,"interventions":2671},[89],[2233,2234,2235],[2204,2237],{"trials":2673,"activeCount":99},[],{"trials":2675,"activeCount":99},[],{"trials":2677,"activeCount":99},[],{"intervention":752,"totalTrials":95,"cells":2679},{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[],{"trials":2685,"activeCount":99},[2686],{"nctId":743,"briefTitle":744,"status":167,"phases":2687,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":2688,"interventions":2689},[89],[750],[752,753,712,754],{"trials":2691,"activeCount":99},[],{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"intervention":2697,"totalTrials":95,"cells":2698},"CDA Inhibitor E7727\u002FDecitabine Combination Agent ASTX727",{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[2705],{"nctId":2706,"briefTitle":2707,"status":153,"phases":2708,"primaryCompletion":2709,"completion":2710,"start":437,"enrollment":99,"conditions":2711,"interventions":2714},"NCT04013880","ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent\u002FRefractory Myelodysplastic Syndrome or Acute Myeloid Leukemia",[88,89],"2021-03-31","2022-03-31",[981,2712,982,2713,983,980],"Myelodysplastic Syndrome","Recurrent Myelodysplastic Syndrome",[2697,2715],"IDH-1 Inhibitor FT-2102",{"trials":2717,"activeCount":99},[],{"trials":2719,"activeCount":99},[],{"trials":2721,"activeCount":99},[],{"intervention":2715,"totalTrials":95,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2725,"activeCount":99},[],{"trials":2727,"activeCount":99},[],{"trials":2729,"activeCount":99},[2730],{"nctId":2706,"briefTitle":2707,"status":153,"phases":2731,"primaryCompletion":2709,"completion":2710,"start":437,"enrollment":99,"conditions":2732,"interventions":2733},[88,89],[981,2712,982,2713,983,980],[2697,2715],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"intervention":2741,"totalTrials":95,"cells":2742},"amifostine trihydrate",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[2749],{"nctId":2750,"briefTitle":2751,"status":167,"phases":2752,"primaryCompletion":1233,"completion":1233,"start":2753,"enrollment":1715,"conditions":2754,"interventions":2757},"NCT00503776","Chemo\u002FXRT +\u002F- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia",[89],"2006-01",[2755,21,1503,2756],"Dysphagia","Xerostomia",[2741],{"trials":2759,"activeCount":99},[],{"trials":2761,"activeCount":99},[],{"trials":2763,"activeCount":99},[],{"intervention":1134,"totalTrials":95,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2776,"PHASE4":2778,"NA":2780},{"trials":2767,"activeCount":99},[],{"trials":2769,"activeCount":99},[],{"trials":2771,"activeCount":99},[2772],{"nctId":1128,"briefTitle":1129,"status":207,"phases":2773,"primaryCompletion":278,"completion":278,"start":1131,"enrollment":344,"conditions":2774,"interventions":2775},[89],[15],[284,1134,287],{"trials":2777,"activeCount":99},[],{"trials":2779,"activeCount":99},[],{"trials":2781,"activeCount":99},[],{"intervention":2783,"totalTrials":95,"cells":2784},"VEGF Trap",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2786,"activeCount":99},[],{"trials":2788,"activeCount":99},[],{"trials":2790,"activeCount":99},[2791],{"nctId":2792,"briefTitle":2793,"status":153,"phases":2794,"primaryCompletion":2437,"completion":769,"start":2795,"enrollment":99,"conditions":2796,"interventions":2797},"NCT00601991","A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia",[89],"2007-03",[35],[2783],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[],{"intervention":2805,"totalTrials":95,"cells":2806},"Avelumab",{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2811,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[2813],{"nctId":2814,"briefTitle":2815,"status":167,"phases":2816,"primaryCompletion":2817,"completion":2817,"start":2818,"enrollment":688,"conditions":2819,"interventions":2821},"NCT03000179","Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma",[89],"2021-08-03","2017-03-03",[2820],"Adenocarcinoma",[2805],{"trials":2823,"activeCount":99},[],{"trials":2825,"activeCount":99},[],{"trials":2827,"activeCount":99},[],{"intervention":1899,"totalTrials":95,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[2836],{"nctId":1893,"briefTitle":1894,"status":153,"phases":2837,"primaryCompletion":1896,"completion":730,"start":1140,"enrollment":99,"conditions":2838,"interventions":2839},[89],[735],[1899,1885,754],{"trials":2841,"activeCount":99},[],{"trials":2843,"activeCount":99},[],{"trials":2845,"activeCount":99},[],{"intervention":774,"totalTrials":95,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[2854],{"nctId":766,"briefTitle":767,"status":167,"phases":2855,"primaryCompletion":769,"completion":770,"start":771,"enrollment":113,"conditions":2856,"interventions":2857},[89],[15],[774,687],{"trials":2859,"activeCount":99},[],{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[],{"intervention":2865,"totalTrials":95,"cells":2866},"Ibrutinib",{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":99},[2873],{"nctId":2874,"briefTitle":2875,"status":207,"phases":2876,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":1801,"conditions":2880,"interventions":2890},"NCT02869633","Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant",[89],"2021-11-18","2023-10","2016-11",[2881,2882,2883,2884,2885,2886,2887,2888,2889],"Blastoid Variant Mantle Cell Lymphoma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Follicular Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Mantle Cell Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Follicular Lymphoma","Refractory Hodgkin Lymphoma","Refractory Mantle Cell Lymphoma",[2865],{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"intervention":1708,"totalTrials":95,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2900,"activeCount":99},[],{"trials":2902,"activeCount":99},[],{"trials":2904,"activeCount":99},[2905],{"nctId":1698,"briefTitle":1699,"status":167,"phases":2906,"primaryCompletion":40,"completion":1701,"start":1702,"enrollment":748,"conditions":2907,"interventions":2908},[88,89],[1704,1705,357,724,358,1706],[310,1708],{"trials":2910,"activeCount":99},[],{"trials":2912,"activeCount":99},[],{"trials":2914,"activeCount":99},[],{"intervention":2916,"totalTrials":95,"cells":2917},"gefitinib",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":99},[2924],{"nctId":2925,"briefTitle":2926,"status":167,"phases":2927,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":95,"conditions":2931,"interventions":2932},"NCT00082667","Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast",[89],"2004-07","2005-06","2002-10",[15],[2916],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[],{"intervention":1824,"totalTrials":95,"cells":2940},{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2951,"PHASE4":2953,"NA":2955},{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[2947],{"nctId":1817,"briefTitle":1818,"status":207,"phases":2948,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":719,"conditions":2949,"interventions":2950},[89],[15],[1824,1122],{"trials":2952,"activeCount":99},[],{"trials":2954,"activeCount":99},[],{"trials":2956,"activeCount":99},[],{"intervention":2958,"totalTrials":95,"cells":2959},"Fluorine F 18 L-glutamate Derivative BAY94-9392",{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2964,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2961,"activeCount":99},[],{"trials":2963,"activeCount":99},[],{"trials":2965,"activeCount":99},[2966],{"nctId":2967,"briefTitle":2968,"status":207,"phases":2969,"primaryCompletion":2970,"completion":2971,"start":2972,"enrollment":719,"conditions":2973,"interventions":2977},"NCT02448225","18F-FSPG PET\u002FCT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules",[89],"2021-08-02","2022-10-10","2015-06-16",[2974,2975,2976],"Lung Carcinoma","Solitary Pulmonary Nodule","Cigarette Smoking Behavior",[2958],{"trials":2979,"activeCount":99},[],{"trials":2981,"activeCount":99},[],{"trials":2983,"activeCount":99},[],{"intervention":2985,"totalTrials":95,"cells":2986},"Enzalutamide",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"trials":2992,"activeCount":99},[2993],{"nctId":2994,"briefTitle":2995,"status":167,"phases":2996,"primaryCompletion":2997,"completion":2998,"start":1976,"enrollment":594,"conditions":2999,"interventions":3002},"NCT02457910","Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer",[88,89],"2018-12","2022-08-08",[1748,3000,410,1749,3001,358,1751],"Estrogen Receptor Positive","Progesterone Receptor Positive",[2985,3003],"Taselisib",{"trials":3005,"activeCount":99},[],{"trials":3007,"activeCount":99},[],{"trials":3009,"activeCount":99},[],{"intervention":3003,"totalTrials":95,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3022,"PHASE4":3024,"NA":3026},{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[],{"trials":3017,"activeCount":99},[3018],{"nctId":2994,"briefTitle":2995,"status":167,"phases":3019,"primaryCompletion":2997,"completion":2998,"start":1976,"enrollment":594,"conditions":3020,"interventions":3021},[88,89],[1748,3000,410,1749,3001,358,1751],[2985,3003],{"trials":3023,"activeCount":99},[],{"trials":3025,"activeCount":99},[],{"trials":3027,"activeCount":99},[],{"intervention":1145,"totalTrials":95,"cells":3029},{"EARLY_PHASE1":3030,"PHASE1":3032,"PHASE2":3034,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[],{"trials":3035,"activeCount":99},[3036],{"nctId":1136,"briefTitle":1137,"status":207,"phases":3037,"primaryCompletion":1139,"completion":1140,"start":818,"enrollment":1141,"conditions":3038,"interventions":3039},[89],[954],[1144,1145,1146,286,1147,287],{"trials":3041,"activeCount":99},[],{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[],{"intervention":3047,"totalTrials":95,"cells":3048},"TdT-mediated dUTP nick end labeling assay",{"EARLY_PHASE1":3049,"PHASE1":3051,"PHASE2":3053,"PHASE3":3064,"PHASE4":3066,"NA":3068},{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[3055],{"nctId":3056,"briefTitle":3057,"status":167,"phases":3058,"primaryCompletion":2042,"completion":3059,"start":3060,"enrollment":403,"conditions":3061,"interventions":3063},"NCT01316692","Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma",[89],"2015-08","2011-10",[2178,3062,2195],"Stage IIIc Melanoma",[3047],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"intervention":3071,"totalTrials":95,"cells":3072},"Cytarabine",{"EARLY_PHASE1":3073,"PHASE1":3075,"PHASE2":3077,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":99},[3079],{"nctId":3080,"briefTitle":3081,"status":207,"phases":3082,"primaryCompletion":3083,"completion":2229,"start":1746,"enrollment":1863,"conditions":3084,"interventions":3092},"NCT02658487","Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia",[89],"2019-04",[3085,3086,3087,3088,3089,3090,3091],"Acute Myeloid Leukemia (AML)","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Acute Myeloid Leukemia With Multilineage Dysplasia","Myeloid Sarcoma","Secondary Acute Myeloid Leukemia","Therapy-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome",[3071,3093],"Vosaroxin",{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"trials":3099,"activeCount":99},[],{"intervention":3093,"totalTrials":95,"cells":3101},{"EARLY_PHASE1":3102,"PHASE1":3104,"PHASE2":3106,"PHASE3":3112,"PHASE4":3114,"NA":3116},{"trials":3103,"activeCount":99},[],{"trials":3105,"activeCount":99},[],{"trials":3107,"activeCount":99},[3108],{"nctId":3080,"briefTitle":3081,"status":207,"phases":3109,"primaryCompletion":3083,"completion":2229,"start":1746,"enrollment":1863,"conditions":3110,"interventions":3111},[89],[3085,3086,3087,3088,3089,3090,3091],[3071,3093],{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":99},[],{"trials":3117,"activeCount":99},[],{"intervention":783,"totalTrials":95,"cells":3119},{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3124,"PHASE3":3130,"PHASE4":3132,"NA":3134},{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[3126],{"nctId":776,"briefTitle":777,"status":153,"phases":3127,"primaryCompletion":779,"completion":779,"start":780,"enrollment":99,"conditions":3128,"interventions":3129},[89],[15],[783,284,784,687],{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[],{"trials":3135,"activeCount":99},[],{"intervention":3137,"totalTrials":95,"cells":3138},"STA-9090",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3140,"activeCount":99},[],{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[3145],{"nctId":3146,"briefTitle":3147,"status":167,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":770,"enrollment":952,"conditions":3150,"interventions":3154},"NCT01227018","PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer",[89],"2013-05",[3151,3152,3153],"Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage IV Pancreatic Cancer",[3137],{"trials":3156,"activeCount":99},[],{"trials":3158,"activeCount":99},[],{"trials":3160,"activeCount":99},[],{"intervention":412,"totalTrials":95,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3164,"activeCount":99},[],{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[3169],{"nctId":399,"briefTitle":400,"status":167,"phases":3170,"primaryCompletion":402,"completion":402,"start":211,"enrollment":403,"conditions":3171,"interventions":3172},[88,89],[405,406,407,408,358,409,410],[245,412,413],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[],{"intervention":413,"totalTrials":95,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3182,"activeCount":99},[],{"trials":3184,"activeCount":99},[],{"trials":3186,"activeCount":99},[3187],{"nctId":399,"briefTitle":400,"status":167,"phases":3188,"primaryCompletion":402,"completion":402,"start":211,"enrollment":403,"conditions":3189,"interventions":3190},[88,89],[405,406,407,408,358,409,410],[245,412,413],{"trials":3192,"activeCount":99},[],{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[],{"intervention":2056,"totalTrials":95,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":99},[],{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[3205],{"nctId":2047,"briefTitle":2048,"status":207,"phases":3206,"primaryCompletion":2050,"completion":2051,"start":732,"enrollment":2052,"conditions":3207,"interventions":3208},[89],[2054],[2056,178,2057,2058,2059,2060,2057],{"trials":3210,"activeCount":99},[],{"trials":3212,"activeCount":99},[],{"trials":3214,"activeCount":99},[],{"intervention":2057,"totalTrials":95,"cells":3216},{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3221,"PHASE3":3227,"PHASE4":3229,"NA":3231},{"trials":3218,"activeCount":99},[],{"trials":3220,"activeCount":99},[],{"trials":3222,"activeCount":99},[3223],{"nctId":2047,"briefTitle":2048,"status":207,"phases":3224,"primaryCompletion":2050,"completion":2051,"start":732,"enrollment":2052,"conditions":3225,"interventions":3226},[89],[2054],[2056,178,2057,2058,2059,2060,2057],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"intervention":2058,"totalTrials":95,"cells":3234},{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3239,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[3241],{"nctId":2047,"briefTitle":2048,"status":207,"phases":3242,"primaryCompletion":2050,"completion":2051,"start":732,"enrollment":2052,"conditions":3243,"interventions":3244},[89],[2054],[2056,178,2057,2058,2059,2060,2057],{"trials":3246,"activeCount":99},[],{"trials":3248,"activeCount":99},[],{"trials":3250,"activeCount":99},[],{"intervention":2059,"totalTrials":95,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3255,"PHASE2":3257,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3254,"activeCount":99},[],{"trials":3256,"activeCount":99},[],{"trials":3258,"activeCount":99},[3259],{"nctId":2047,"briefTitle":2048,"status":207,"phases":3260,"primaryCompletion":2050,"completion":2051,"start":732,"enrollment":2052,"conditions":3261,"interventions":3262},[89],[2054],[2056,178,2057,2058,2059,2060,2057],{"trials":3264,"activeCount":99},[],{"trials":3266,"activeCount":99},[],{"trials":3268,"activeCount":99},[],{"intervention":2060,"totalTrials":95,"cells":3270},{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3275,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":99},[3277],{"nctId":2047,"briefTitle":2048,"status":207,"phases":3278,"primaryCompletion":2050,"completion":2051,"start":732,"enrollment":2052,"conditions":3279,"interventions":3280},[89],[2054],[2056,178,2057,2058,2059,2060,2057],{"trials":3282,"activeCount":99},[],{"trials":3284,"activeCount":99},[],{"trials":3286,"activeCount":99},[],{"intervention":2129,"totalTrials":95,"cells":3288},{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3293,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[],{"trials":3294,"activeCount":99},[3295],{"nctId":2120,"briefTitle":2121,"status":167,"phases":3296,"primaryCompletion":2123,"completion":697,"start":2124,"enrollment":2125,"conditions":3297,"interventions":3298},[88,89],[2127,1237,27],[2129,2130,2129,1983],{"trials":3300,"activeCount":99},[],{"trials":3302,"activeCount":99},[],{"trials":3304,"activeCount":99},[],{"intervention":3306,"totalTrials":95,"cells":3307},"ABT-751",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3309,"activeCount":99},[],{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[3314],{"nctId":3315,"briefTitle":3316,"status":167,"phases":3317,"primaryCompletion":780,"completion":780,"start":3318,"enrollment":16,"conditions":3319,"interventions":3321},"NCT00471718","ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy",[88,89],"2004-01",[3320],"Prostate Cancer",[3306],{"trials":3323,"activeCount":99},[],{"trials":3325,"activeCount":99},[],{"trials":3327,"activeCount":99},[],{"intervention":3329,"totalTrials":95,"cells":3330},"Eflornithine",{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3335,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[3337],{"nctId":3338,"briefTitle":3339,"status":207,"phases":3340,"primaryCompletion":3341,"completion":3342,"start":3343,"enrollment":3344,"conditions":3345,"interventions":3347},"NCT02794428","Chemoprevention of Gastric Carcinogenesis",[89],"2022-12-20","2024-07-01","2016-09-19",91,[954,3346],"Gastric Intestinal Metaplasia",[3329],{"trials":3349,"activeCount":99},[],{"trials":3351,"activeCount":99},[],{"trials":3353,"activeCount":99},[],{"intervention":163,"totalTrials":257,"cells":3355},{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3374,"PHASE3":3376,"PHASE4":3378,"NA":3380},{"trials":3357,"activeCount":99},[],{"trials":3359,"activeCount":99},[3360,3364],{"nctId":151,"briefTitle":152,"status":153,"phases":3361,"primaryCompletion":155,"completion":156,"start":157,"enrollment":99,"conditions":3362,"interventions":3363},[88],[159,160,161],[144,163],{"nctId":3365,"briefTitle":3366,"status":167,"phases":3367,"primaryCompletion":3368,"completion":3368,"start":3369,"enrollment":22,"conditions":3370,"interventions":3372},"NCT03054038","Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer",[88],"2022-03-23","2017-07-20",[3371],"Non-Small Cell Lung Carcinoma",[163,3373],"Necitumumab",{"trials":3375,"activeCount":99},[],{"trials":3377,"activeCount":99},[],{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[],{"intervention":3383,"totalTrials":257,"cells":3384},"capecitabine",{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3402,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[3389,3398],{"nctId":3390,"briefTitle":3391,"status":207,"phases":3392,"primaryCompletion":3393,"completion":3393,"start":769,"enrollment":3394,"conditions":3395,"interventions":3396},"NCT00983268","Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer",[88],"2013-02",21,[821,1622],[3383,3397],"vorinostat",{"nctId":2074,"briefTitle":2075,"status":153,"phases":3399,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":99,"conditions":3400,"interventions":3401},[88],[2081,2082,2083,2084,2085,2086,2087,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,2107,2108,2109],[2111,1983,2112],{"trials":3403,"activeCount":99},[],{"trials":3405,"activeCount":99},[],{"trials":3407,"activeCount":99},[],{"trials":3409,"activeCount":99},[],{"intervention":823,"totalTrials":257,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[3416,3420],{"nctId":1612,"briefTitle":1613,"status":207,"phases":3417,"primaryCompletion":1615,"completion":1616,"start":1617,"enrollment":1618,"conditions":3418,"interventions":3419},[88],[1620,1621,1342,821,1622,1623],[284,823,1146],{"nctId":815,"briefTitle":816,"status":207,"phases":3421,"primaryCompletion":818,"completion":278,"start":819,"enrollment":30,"conditions":3422,"interventions":3423},[88],[821],[792,823],{"trials":3425,"activeCount":99},[],{"trials":3427,"activeCount":99},[],{"trials":3429,"activeCount":99},[],{"trials":3431,"activeCount":99},[],{"intervention":2258,"totalTrials":257,"cells":3433},{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3448,"PHASE3":3450,"PHASE4":3452,"NA":3454},{"trials":3435,"activeCount":99},[],{"trials":3437,"activeCount":99},[3438,3442],{"nctId":2251,"briefTitle":2252,"status":207,"phases":3439,"primaryCompletion":2254,"completion":1212,"start":1176,"enrollment":1978,"conditions":3440,"interventions":3441},[88],[15],[2257,2258],{"nctId":3443,"briefTitle":3444,"status":167,"phases":3445,"primaryCompletion":1140,"completion":1140,"start":1340,"enrollment":439,"conditions":3446,"interventions":3447},"NCT00892801","Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer",[88],[18,1070],[2258],{"trials":3449,"activeCount":99},[],{"trials":3451,"activeCount":99},[],{"trials":3453,"activeCount":99},[],{"trials":3455,"activeCount":99},[],{"intervention":1753,"totalTrials":95,"cells":3457},{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3459,"activeCount":99},[],{"trials":3461,"activeCount":99},[3462],{"nctId":1741,"briefTitle":1742,"status":207,"phases":3463,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":868,"conditions":3464,"interventions":3465},[88],[1748,410,1749,1750,358,1751],[1753,1754],{"trials":3467,"activeCount":99},[],{"trials":3469,"activeCount":99},[],{"trials":3471,"activeCount":99},[],{"trials":3473,"activeCount":99},[],{"intervention":3373,"totalTrials":95,"cells":3475},{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3484,"PHASE3":3486,"PHASE4":3488,"NA":3490},{"trials":3477,"activeCount":99},[],{"trials":3479,"activeCount":99},[3480],{"nctId":3365,"briefTitle":3366,"status":167,"phases":3481,"primaryCompletion":3368,"completion":3368,"start":3369,"enrollment":22,"conditions":3482,"interventions":3483},[88],[3371],[163,3373],{"trials":3485,"activeCount":99},[],{"trials":3487,"activeCount":99},[],{"trials":3489,"activeCount":99},[],{"trials":3491,"activeCount":99},[],{"intervention":3397,"totalTrials":95,"cells":3493},{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3502,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[3498],{"nctId":3390,"briefTitle":3391,"status":207,"phases":3499,"primaryCompletion":3393,"completion":3393,"start":769,"enrollment":3394,"conditions":3500,"interventions":3501},[88],[821,1622],[3383,3397],{"trials":3503,"activeCount":99},[],{"trials":3505,"activeCount":99},[],{"trials":3507,"activeCount":99},[],{"trials":3509,"activeCount":99},[],{"intervention":737,"totalTrials":95,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3520,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3513,"activeCount":99},[],{"trials":3515,"activeCount":99},[3516],{"nctId":727,"briefTitle":728,"status":207,"phases":3517,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":3518,"interventions":3519},[88],[735],[737,738,712,739],{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[],{"trials":3525,"activeCount":99},[],{"trials":3527,"activeCount":99},[],{"intervention":738,"totalTrials":95,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3538,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3531,"activeCount":99},[],{"trials":3533,"activeCount":99},[3534],{"nctId":727,"briefTitle":728,"status":207,"phases":3535,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":3536,"interventions":3537},[88],[735],[737,738,712,739],{"trials":3539,"activeCount":99},[],{"trials":3541,"activeCount":99},[],{"trials":3543,"activeCount":99},[],{"trials":3545,"activeCount":99},[],{"intervention":739,"totalTrials":95,"cells":3547},{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3556,"PHASE3":3558,"PHASE4":3560,"NA":3562},{"trials":3549,"activeCount":99},[],{"trials":3551,"activeCount":99},[3552],{"nctId":727,"briefTitle":728,"status":207,"phases":3553,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":3554,"interventions":3555},[88],[735],[737,738,712,739],{"trials":3557,"activeCount":99},[],{"trials":3559,"activeCount":99},[],{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[],{"intervention":1763,"totalTrials":95,"cells":3565},{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3574,"PHASE3":3576,"PHASE4":3578,"NA":3580},{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[3570],{"nctId":1756,"briefTitle":1757,"status":207,"phases":3571,"primaryCompletion":1759,"completion":1759,"start":1760,"enrollment":113,"conditions":3572,"interventions":3573},[88],[18],[1763,285],{"trials":3575,"activeCount":99},[],{"trials":3577,"activeCount":99},[],{"trials":3579,"activeCount":99},[],{"trials":3581,"activeCount":99},[],{"intervention":3583,"totalTrials":95,"cells":3584},"sorafenib tosylate",{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3597,"PHASE3":3599,"PHASE4":3601,"NA":3603},{"trials":3586,"activeCount":99},[],{"trials":3588,"activeCount":99},[3589],{"nctId":3590,"briefTitle":3591,"status":207,"phases":3592,"primaryCompletion":1499,"completion":3593,"start":1140,"enrollment":1801,"conditions":3594,"interventions":3596},"NCT01276210","Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases",[88],"2017-06",[3595],"Tumors Metastatic to Brain",[3583],{"trials":3598,"activeCount":99},[],{"trials":3600,"activeCount":99},[],{"trials":3602,"activeCount":99},[],{"trials":3604,"activeCount":99},[],{"intervention":3606,"totalTrials":95,"cells":3607},"[18F]-fluorodeoxythymidine",{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3619,"PHASE3":3621,"PHASE4":3623,"NA":3625},{"trials":3609,"activeCount":99},[],{"trials":3611,"activeCount":99},[3612],{"nctId":3613,"briefTitle":3614,"status":207,"phases":3615,"primaryCompletion":730,"completion":1615,"start":1268,"enrollment":439,"conditions":3616,"interventions":3618},"NCT01207895","Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer",[88],[3617],"Rectal Cancer",[3606],{"trials":3620,"activeCount":99},[],{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[],{"trials":3626,"activeCount":99},[],{"intervention":3628,"totalTrials":95,"cells":3629},"High-Dose Trivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3644,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3631,"activeCount":99},[],{"trials":3633,"activeCount":99},[3634],{"nctId":3635,"briefTitle":3636,"status":207,"phases":3637,"primaryCompletion":3638,"completion":2560,"start":3639,"enrollment":2043,"conditions":3640,"interventions":3642},"NCT01215734","Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients",[88],"2012-04","2010-10",[3641],"Adult Stem Cell Hematopoetic Transplant",[3628,3643],"Standard Dose Trivalent Inactivated Flu Vaccine",{"trials":3645,"activeCount":99},[],{"trials":3647,"activeCount":99},[],{"trials":3649,"activeCount":99},[],{"trials":3651,"activeCount":99},[],{"intervention":3643,"totalTrials":95,"cells":3653},{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3662,"PHASE3":3664,"PHASE4":3666,"NA":3668},{"trials":3655,"activeCount":99},[],{"trials":3657,"activeCount":99},[3658],{"nctId":3635,"briefTitle":3636,"status":207,"phases":3659,"primaryCompletion":3638,"completion":2560,"start":3639,"enrollment":2043,"conditions":3660,"interventions":3661},[88],[3641],[3628,3643],{"trials":3663,"activeCount":99},[],{"trials":3665,"activeCount":99},[],{"trials":3667,"activeCount":99},[],{"trials":3669,"activeCount":99},[],{"intervention":3671,"totalTrials":95,"cells":3672},"imatinib mesylate",{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3685,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3674,"activeCount":99},[],{"trials":3676,"activeCount":99},[3677],{"nctId":3678,"briefTitle":3679,"status":167,"phases":3680,"primaryCompletion":2561,"completion":1118,"start":771,"enrollment":113,"conditions":3681,"interventions":3683},"NCT00573404","Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors",[88],[3682],"Gastrointestinal Stromal Tumor",[3671,3684],"sunitinib malate",{"trials":3686,"activeCount":99},[],{"trials":3688,"activeCount":99},[],{"trials":3690,"activeCount":99},[],{"trials":3692,"activeCount":99},[],{"intervention":3684,"totalTrials":95,"cells":3694},{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3703,"PHASE3":3705,"PHASE4":3707,"NA":3709},{"trials":3696,"activeCount":99},[],{"trials":3698,"activeCount":99},[3699],{"nctId":3678,"briefTitle":3679,"status":167,"phases":3700,"primaryCompletion":2561,"completion":1118,"start":771,"enrollment":113,"conditions":3701,"interventions":3702},[88],[3682],[3671,3684],{"trials":3704,"activeCount":99},[],{"trials":3706,"activeCount":99},[],{"trials":3708,"activeCount":99},[],{"trials":3710,"activeCount":99},[],{"intervention":3712,"totalTrials":95,"cells":3713},"TGR-1202",{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3729,"PHASE3":3731,"PHASE4":3733,"NA":3735},{"trials":3715,"activeCount":99},[],{"trials":3717,"activeCount":99},[3718],{"nctId":3719,"briefTitle":3720,"status":207,"phases":3721,"primaryCompletion":3722,"completion":3723,"start":1499,"enrollment":977,"conditions":3724,"interventions":3727},"NCT02493530","TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS\u002FMPN Polycythemia Vera Resistant to Hydroxyurea",[88],"2023-03-21","2024-05",[3725,3726],"Myelofibrosis","Polycythemia Vera",[3712,3728],"ruxolitinib",{"trials":3730,"activeCount":99},[],{"trials":3732,"activeCount":99},[],{"trials":3734,"activeCount":99},[],{"trials":3736,"activeCount":99},[],{"intervention":3728,"totalTrials":95,"cells":3738},{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3747,"PHASE3":3749,"PHASE4":3751,"NA":3753},{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[3743],{"nctId":3719,"briefTitle":3720,"status":207,"phases":3744,"primaryCompletion":3722,"completion":3723,"start":1499,"enrollment":977,"conditions":3745,"interventions":3746},[88],[3725,3726],[3712,3728],{"trials":3748,"activeCount":99},[],{"trials":3750,"activeCount":99},[],{"trials":3752,"activeCount":99},[],{"trials":3754,"activeCount":99},[],{"intervention":1884,"totalTrials":95,"cells":3756},{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3765,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3758,"activeCount":99},[],{"trials":3760,"activeCount":99},[3761],{"nctId":1879,"briefTitle":1880,"status":153,"phases":3762,"enrollment":99,"conditions":3763,"interventions":3764},[88],[735],[1884,1885,754],{"trials":3766,"activeCount":99},[],{"trials":3768,"activeCount":99},[],{"trials":3770,"activeCount":99},[],{"trials":3772,"activeCount":99},[],{"intervention":2112,"totalTrials":95,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3776,"activeCount":99},[],{"trials":3778,"activeCount":99},[3779],{"nctId":2074,"briefTitle":2075,"status":153,"phases":3780,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":99,"conditions":3781,"interventions":3782},[88],[2081,2082,2083,2084,2085,2086,2087,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,2107,2108,2109],[2111,1983,2112],{"trials":3784,"activeCount":99},[],{"trials":3786,"activeCount":99},[],{"trials":3788,"activeCount":99},[],{"trials":3790,"activeCount":99},[],{"intervention":3792,"totalTrials":95,"cells":3793},"Erdafitinib",{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3809,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3795,"activeCount":99},[],{"trials":3797,"activeCount":99},[3798],{"nctId":3799,"briefTitle":3800,"status":207,"phases":3801,"primaryCompletion":3802,"completion":3803,"start":3804,"enrollment":11,"conditions":3805,"interventions":3806},"NCT03238196","Fulvestrant, Palbociclib and Erdafitinib in ER+\u002FHER2-\u002FFGFR-amplified Metastatic Breast Cancer",[88],"2021-04-30","2024-03-20","2017-08-18",[735],[3792,3807,3808],"Palbociclib","Fulvestrant",{"trials":3810,"activeCount":99},[],{"trials":3812,"activeCount":99},[],{"trials":3814,"activeCount":99},[],{"trials":3816,"activeCount":99},[],{"intervention":3807,"totalTrials":95,"cells":3818},{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3827,"PHASE3":3829,"PHASE4":3831,"NA":3833},{"trials":3820,"activeCount":99},[],{"trials":3822,"activeCount":99},[3823],{"nctId":3799,"briefTitle":3800,"status":207,"phases":3824,"primaryCompletion":3802,"completion":3803,"start":3804,"enrollment":11,"conditions":3825,"interventions":3826},[88],[735],[3792,3807,3808],{"trials":3828,"activeCount":99},[],{"trials":3830,"activeCount":99},[],{"trials":3832,"activeCount":99},[],{"trials":3834,"activeCount":99},[],{"intervention":3808,"totalTrials":95,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3838,"activeCount":99},[],{"trials":3840,"activeCount":99},[3841],{"nctId":3799,"briefTitle":3800,"status":207,"phases":3842,"primaryCompletion":3802,"completion":3803,"start":3804,"enrollment":11,"conditions":3843,"interventions":3844},[88],[735],[3792,3807,3808],{"trials":3846,"activeCount":99},[],{"trials":3848,"activeCount":99},[],{"trials":3850,"activeCount":99},[],{"trials":3852,"activeCount":99},[],{"intervention":3854,"totalTrials":95,"cells":3855},"lithium carbonate",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3868,"PHASE3":3870,"PHASE4":3872,"NA":3874},{"trials":3857,"activeCount":99},[],{"trials":3859,"activeCount":99},[3860],{"nctId":3861,"briefTitle":3862,"status":167,"phases":3863,"primaryCompletion":2437,"completion":2437,"start":1195,"enrollment":30,"conditions":3864,"interventions":3867},"NCT00469937","Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases",[88],[2127,3865,3866,27],"Cognitive\u002FFunctional Effects","Neurotoxicity",[3854],{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[],{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[],{"intervention":3877,"totalTrials":95,"cells":3878},"Entinostat",{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3904,"PHASE3":3906,"PHASE4":3908,"NA":3910},{"trials":3880,"activeCount":99},[],{"trials":3882,"activeCount":99},[3883],{"nctId":3884,"briefTitle":3885,"status":167,"phases":3886,"primaryCompletion":3887,"completion":3887,"start":3888,"enrollment":793,"conditions":3889,"interventions":3902},"NCT03924245","Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers",[88],"2022-02-04","2020-10-01",[2440,3890,3891,3892,3893,3894,3895,3896,3897,3898,3899,3900,3901],"Fallopian Tube Carcinosarcoma","Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","High Grade Fallopian Tube Serous Adenocarcinoma","High Grade Ovarian Serous Adenocarcinoma","Ovarian Carcinosarcoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma","Recurrent Endometrial Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[3877,3903],"Olaparib",{"trials":3905,"activeCount":99},[],{"trials":3907,"activeCount":99},[],{"trials":3909,"activeCount":99},[],{"trials":3911,"activeCount":99},[],{"intervention":3903,"totalTrials":95,"cells":3913},{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3922,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3915,"activeCount":99},[],{"trials":3917,"activeCount":99},[3918],{"nctId":3884,"briefTitle":3885,"status":167,"phases":3919,"primaryCompletion":3887,"completion":3887,"start":3888,"enrollment":793,"conditions":3920,"interventions":3921},[88],[2440,3890,3891,3892,3893,3894,3895,3896,3897,3898,3899,3900,3901],[3877,3903],{"trials":3923,"activeCount":99},[],{"trials":3925,"activeCount":99},[],{"trials":3927,"activeCount":99},[],{"trials":3929,"activeCount":99},[],{"intervention":3931,"totalTrials":95,"cells":3932},"acetylsalicylic acid",{"EARLY_PHASE1":3933,"PHASE1":3950,"PHASE2":3952,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3934,"activeCount":99},[3935],{"nctId":3936,"briefTitle":3937,"status":167,"phases":3938,"primaryCompletion":3939,"completion":2191,"start":3940,"enrollment":9,"conditions":3941,"interventions":3949},"NCT01707823","Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer",[87],"2018-06","2012-10",[3942,306,3943,3944,3945,3946,3947,3948],"Adenocarcinoma of the Lung","Stage IA Non-small Cell Lung Cancer","Stage IB Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[3931],{"trials":3951,"activeCount":99},[],{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":99},[],{"trials":3959,"activeCount":99},[],{"intervention":3961,"totalTrials":95,"cells":3962},"F-18 16 Alpha-Fluoroestradiol",{"EARLY_PHASE1":3963,"PHASE1":3973,"PHASE2":3975,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3964,"activeCount":99},[3965],{"nctId":3966,"briefTitle":3967,"status":167,"phases":3968,"primaryCompletion":1175,"completion":2079,"start":1701,"enrollment":793,"conditions":3969,"interventions":3972},"NCT02374931","18F-FES PET\u002FCT in Imaging Patients With Desmoid Tumors",[87],[3970,3971],"Deep Fibromatosis\u002FDesmoid Tumor","Familial Adenomatous Polyposis",[3961],{"trials":3974,"activeCount":99},[],{"trials":3976,"activeCount":99},[],{"trials":3978,"activeCount":99},[],{"trials":3980,"activeCount":99},[],{"trials":3982,"activeCount":99},[],{"intervention":3984,"totalTrials":95,"cells":3985},"IV administration of gadolinium-containing contrast agent",{"EARLY_PHASE1":3986,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4009,"NA":4011},{"trials":3987,"activeCount":99},[3988],{"nctId":3989,"briefTitle":3990,"status":167,"phases":3991,"primaryCompletion":3992,"completion":3993,"start":2583,"enrollment":33,"conditions":3994,"interventions":4002},"NCT01996527","3T MRI Biomarkers of Glioma Treatment Response",[87],"2015-11-23","2016-01-01",[3995,3996,3997,3998,3999,4000,4001],"Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Recurrent Adult Brain Tumor",[3984],{"trials":4004,"activeCount":99},[],{"trials":4006,"activeCount":99},[],{"trials":4008,"activeCount":99},[],{"trials":4010,"activeCount":99},[],{"trials":4012,"activeCount":99},[],{"intervention":288,"totalTrials":33,"cells":4014},{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4016,"activeCount":99},[],{"trials":4018,"activeCount":99},[],{"trials":4020,"activeCount":99},[4021,4025],{"nctId":273,"briefTitle":274,"status":207,"phases":4022,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":4023,"interventions":4024},[89],[18],[282,283,284,285,286,287,288],{"nctId":827,"briefTitle":828,"status":207,"phases":4026,"primaryCompletion":341,"completion":830,"start":831,"enrollment":832,"conditions":4027,"interventions":4028},[89],[29],[792,835,288],{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":99},[],{"trials":4034,"activeCount":99},[4035,4043,4050,4054,4058],{"nctId":4036,"briefTitle":4037,"status":207,"phases":4038,"primaryCompletion":4039,"completion":4039,"start":1204,"enrollment":8,"conditions":4040,"interventions":4042},"NCT00899457","Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants",[],"2010-08",[4041,18],"Healthy, no Evidence of Disease",[288],{"nctId":4044,"briefTitle":4045,"status":207,"phases":4046,"primaryCompletion":819,"completion":4047,"start":760,"enrollment":594,"conditions":4048,"interventions":4049},"NCT00656604","Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics",[92],"2008-01",[15],[288],{"nctId":1337,"briefTitle":1338,"status":153,"phases":4051,"primaryCompletion":1340,"completion":1340,"start":771,"enrollment":99,"conditions":4052,"interventions":4053},[],[1342],[71,1344,1258,1259,288],{"nctId":1265,"briefTitle":1266,"status":207,"phases":4055,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":4056,"interventions":4057},[],[15,1272,1273,1274,35,24,1275,32,1276,1277,1160,1278],[286,1169,1147,288],{"nctId":1209,"briefTitle":1210,"status":167,"phases":4059,"primaryCompletion":1212,"completion":779,"start":1213,"enrollment":1214,"conditions":4060,"interventions":4061},[],[18],[287,288],{"intervention":835,"totalTrials":439,"cells":4063},{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4068,"PHASE3":4082,"PHASE4":4084,"NA":4086},{"trials":4065,"activeCount":99},[],{"trials":4067,"activeCount":99},[],{"trials":4069,"activeCount":99},[4070,4074,4078],{"nctId":2146,"briefTitle":2147,"status":207,"phases":4071,"primaryCompletion":2149,"completion":697,"start":1205,"enrollment":19,"conditions":4072,"interventions":4073},[89],[29],[835,1144],{"nctId":1797,"briefTitle":1798,"status":167,"phases":4075,"primaryCompletion":277,"completion":1800,"start":278,"enrollment":1801,"conditions":4076,"interventions":4077},[89],[18],[835,371,309],{"nctId":827,"briefTitle":828,"status":207,"phases":4079,"primaryCompletion":341,"completion":830,"start":831,"enrollment":832,"conditions":4080,"interventions":4081},[89],[29],[792,835,288],{"trials":4083,"activeCount":99},[],{"trials":4085,"activeCount":99},[],{"trials":4087,"activeCount":99},[4088,4092],{"nctId":1200,"briefTitle":1201,"status":167,"phases":4089,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":25,"conditions":4090,"interventions":4091},[92],[29],[835,286,287],{"nctId":4093,"briefTitle":4094,"status":207,"phases":4095,"primaryCompletion":4096,"completion":4047,"start":4097,"enrollment":22,"conditions":4098,"interventions":4099},"NCT00653250","Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer",[92],"2006-03","2000-12",[18],[835],{"intervention":1147,"totalTrials":9,"cells":4101},{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4112,"PHASE4":4114,"NA":4116},{"trials":4103,"activeCount":99},[],{"trials":4105,"activeCount":99},[],{"trials":4107,"activeCount":99},[4108],{"nctId":1136,"briefTitle":1137,"status":207,"phases":4109,"primaryCompletion":1139,"completion":1140,"start":818,"enrollment":1141,"conditions":4110,"interventions":4111},[89],[954],[1144,1145,1146,286,1147,287],{"trials":4113,"activeCount":99},[],{"trials":4115,"activeCount":99},[],{"trials":4117,"activeCount":99},[4118,4128,4132],{"nctId":4119,"briefTitle":4120,"status":167,"phases":4121,"primaryCompletion":40,"completion":4122,"start":2254,"enrollment":4123,"conditions":4124,"interventions":4126},"NCT00949052","Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer",[],"2018-02",1000,[4125],"Cancer",[4127,1147],"DNA analysis",{"nctId":1265,"briefTitle":1266,"status":207,"phases":4129,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":4130,"interventions":4131},[],[15,1272,1273,1274,35,24,1275,32,1276,1277,1160,1278],[286,1169,1147,288],{"nctId":4133,"briefTitle":4134,"status":167,"phases":4135,"primaryCompletion":759,"completion":759,"start":830,"enrollment":4136,"conditions":4137,"interventions":4138},"NCT00957736","Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant",[],252,[4125],[1147],{"intervention":1410,"totalTrials":793,"cells":4140},{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4149,"NA":4155},{"trials":4142,"activeCount":99},[],{"trials":4144,"activeCount":99},[],{"trials":4146,"activeCount":99},[],{"trials":4148,"activeCount":99},[],{"trials":4150,"activeCount":99},[4151],{"nctId":1401,"briefTitle":1402,"status":207,"phases":4152,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":235,"conditions":4153,"interventions":4154},[91],[1407,1408],[1388,1410,1411],{"trials":4156,"activeCount":99},[4157,4169],{"nctId":4158,"briefTitle":4159,"status":167,"phases":4160,"primaryCompletion":697,"completion":4161,"start":4162,"enrollment":113,"conditions":4163,"interventions":4164},"NCT00608517","Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w\u002F Tacrolimus & Mycophenolate Mofetil",[92],"2011-05","2005-09",[1274,35,24,1275,32],[4165,4166,4167,4168],"anti-thymocyte globulin","cyclophosphamide","fludarabine phosphate","methylprednisolone",{"nctId":4170,"briefTitle":4171,"status":4172,"phases":4173,"primaryCompletion":4174,"completion":4175,"start":3149,"enrollment":4176,"conditions":4177,"interventions":4180},"NCT01850108","Non-Myeloablative Conditioning and Bone Marrow Transplantation","UNKNOWN",[92],"2023-11","2024-12-31",26,[4178,4179],"Sickle Cell Disease","Hemoglobinopathies",[4181,1411,1410,4182,4183,4184],"Thymoglobulin","Mesna","Sirolimus","Mycophenolate mofetil",{"intervention":1258,"totalTrials":257,"cells":4186},{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4195,"NA":4197},{"trials":4188,"activeCount":99},[],{"trials":4190,"activeCount":99},[],{"trials":4192,"activeCount":99},[],{"trials":4194,"activeCount":99},[],{"trials":4196,"activeCount":99},[],{"trials":4198,"activeCount":99},[4199,4203],{"nctId":1250,"briefTitle":1251,"status":207,"phases":4200,"primaryCompletion":1204,"completion":1204,"start":1253,"enrollment":1254,"conditions":4201,"interventions":4202},[],[21],[1257,286,1258,1259],{"nctId":1337,"briefTitle":1338,"status":153,"phases":4204,"primaryCompletion":1340,"completion":1340,"start":771,"enrollment":99,"conditions":4205,"interventions":4206},[],[1342],[71,1344,1258,1259,288],{"intervention":1259,"totalTrials":257,"cells":4208},{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4219},{"trials":4210,"activeCount":99},[],{"trials":4212,"activeCount":99},[],{"trials":4214,"activeCount":99},[],{"trials":4216,"activeCount":99},[],{"trials":4218,"activeCount":99},[],{"trials":4220,"activeCount":99},[4221,4225],{"nctId":1250,"briefTitle":1251,"status":207,"phases":4222,"primaryCompletion":1204,"completion":1204,"start":1253,"enrollment":1254,"conditions":4223,"interventions":4224},[],[21],[1257,286,1258,1259],{"nctId":1337,"briefTitle":1338,"status":153,"phases":4226,"primaryCompletion":1340,"completion":1340,"start":771,"enrollment":99,"conditions":4227,"interventions":4228},[],[1342],[71,1344,1258,1259,288],{"intervention":1411,"totalTrials":257,"cells":4230},{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4237,"PHASE4":4239,"NA":4245},{"trials":4232,"activeCount":99},[],{"trials":4234,"activeCount":99},[],{"trials":4236,"activeCount":99},[],{"trials":4238,"activeCount":99},[],{"trials":4240,"activeCount":99},[4241],{"nctId":1401,"briefTitle":1402,"status":207,"phases":4242,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":235,"conditions":4243,"interventions":4244},[91],[1407,1408],[1388,1410,1411],{"trials":4246,"activeCount":99},[4247],{"nctId":4170,"briefTitle":4171,"status":4172,"phases":4248,"primaryCompletion":4174,"completion":4175,"start":3149,"enrollment":4176,"conditions":4249,"interventions":4250},[92],[4178,4179],[4181,1411,1410,4182,4183,4184],{"intervention":1257,"totalTrials":95,"cells":4252},{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4257,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4254,"activeCount":99},[],{"trials":4256,"activeCount":99},[],{"trials":4258,"activeCount":99},[],{"trials":4260,"activeCount":99},[],{"trials":4262,"activeCount":99},[],{"trials":4264,"activeCount":99},[4265],{"nctId":1250,"briefTitle":1251,"status":207,"phases":4266,"primaryCompletion":1204,"completion":1204,"start":1253,"enrollment":1254,"conditions":4267,"interventions":4268},[],[21],[1257,286,1258,1259],{"intervention":4270,"totalTrials":95,"cells":4271},"Oral Glucose Tolerance Test",{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4278,"PHASE4":4280,"NA":4282},{"trials":4273,"activeCount":99},[],{"trials":4275,"activeCount":99},[],{"trials":4277,"activeCount":99},[],{"trials":4279,"activeCount":99},[],{"trials":4281,"activeCount":99},[],{"trials":4283,"activeCount":99},[4284],{"nctId":4285,"briefTitle":4286,"status":4172,"phases":4287,"primaryCompletion":4288,"completion":50,"start":4289,"enrollment":4290,"conditions":4291,"interventions":4293},"NCT03415139","Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant",[],"2023-04","2019-03-12",120,[4292,4125],"Diabetes Mellitus",[4270,4294,4295],"2 OGTTs with and without GLP-1 analogue","Hyperglycemic clamp procedure",{"intervention":4294,"totalTrials":95,"cells":4297},{"EARLY_PHASE1":4298,"PHASE1":4300,"PHASE2":4302,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4299,"activeCount":99},[],{"trials":4301,"activeCount":99},[],{"trials":4303,"activeCount":99},[],{"trials":4305,"activeCount":99},[],{"trials":4307,"activeCount":99},[],{"trials":4309,"activeCount":99},[4310],{"nctId":4285,"briefTitle":4286,"status":4172,"phases":4311,"primaryCompletion":4288,"completion":50,"start":4289,"enrollment":4290,"conditions":4312,"interventions":4313},[],[4292,4125],[4270,4294,4295],{"intervention":4295,"totalTrials":95,"cells":4315},{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4320,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4317,"activeCount":99},[],{"trials":4319,"activeCount":99},[],{"trials":4321,"activeCount":99},[],{"trials":4323,"activeCount":99},[],{"trials":4325,"activeCount":99},[],{"trials":4327,"activeCount":99},[4328],{"nctId":4285,"briefTitle":4286,"status":4172,"phases":4329,"primaryCompletion":4288,"completion":50,"start":4289,"enrollment":4290,"conditions":4330,"interventions":4331},[],[4292,4125],[4270,4294,4295],{"intervention":4333,"totalTrials":95,"cells":4334},"aprepitant",{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4341,"PHASE4":4343,"NA":4345},{"trials":4336,"activeCount":99},[],{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[],{"trials":4342,"activeCount":99},[],{"trials":4344,"activeCount":99},[],{"trials":4346,"activeCount":99},[4347],{"nctId":4348,"briefTitle":4349,"status":153,"phases":4350,"primaryCompletion":4047,"completion":697,"start":818,"enrollment":99,"conditions":4351,"interventions":4355},"NCT00499668","Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer",[92],[4352,35,24,4353,1275,32,4354,27],"Myeloproliferative Disorders","Lymphoproliferative Disorder","Nausea and Vomiting",[4333,4356],"ondansetron hydrochloride",{"intervention":4356,"totalTrials":95,"cells":4358},{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4365,"PHASE4":4367,"NA":4369},{"trials":4360,"activeCount":99},[],{"trials":4362,"activeCount":99},[],{"trials":4364,"activeCount":99},[],{"trials":4366,"activeCount":99},[],{"trials":4368,"activeCount":99},[],{"trials":4370,"activeCount":99},[4371],{"nctId":4348,"briefTitle":4349,"status":153,"phases":4372,"primaryCompletion":4047,"completion":697,"start":818,"enrollment":99,"conditions":4373,"interventions":4374},[92],[4352,35,24,4353,1275,32,4354,27],[4333,4356],{"intervention":4376,"totalTrials":95,"cells":4377},"infliximab",{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4379,"activeCount":99},[],{"trials":4381,"activeCount":99},[],{"trials":4383,"activeCount":99},[],{"trials":4385,"activeCount":99},[],{"trials":4387,"activeCount":99},[],{"trials":4389,"activeCount":99},[4390],{"nctId":4391,"briefTitle":4392,"status":167,"phases":4393,"primaryCompletion":1233,"completion":1233,"start":2613,"enrollment":33,"conditions":4394,"interventions":4395},"NCT00897312","Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease",[],[1237],[4376,4396,4397,4398],"pegylated interferon alfa","ticilimumab","ribavirin",{"intervention":4396,"totalTrials":95,"cells":4400},{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4405,"PHASE3":4407,"PHASE4":4409,"NA":4411},{"trials":4402,"activeCount":99},[],{"trials":4404,"activeCount":99},[],{"trials":4406,"activeCount":99},[],{"trials":4408,"activeCount":99},[],{"trials":4410,"activeCount":99},[],{"trials":4412,"activeCount":99},[4413],{"nctId":4391,"briefTitle":4392,"status":167,"phases":4414,"primaryCompletion":1233,"completion":1233,"start":2613,"enrollment":33,"conditions":4415,"interventions":4416},[],[1237],[4376,4396,4397,4398],{"intervention":4397,"totalTrials":95,"cells":4418},{"EARLY_PHASE1":4419,"PHASE1":4421,"PHASE2":4423,"PHASE3":4425,"PHASE4":4427,"NA":4429},{"trials":4420,"activeCount":99},[],{"trials":4422,"activeCount":99},[],{"trials":4424,"activeCount":99},[],{"trials":4426,"activeCount":99},[],{"trials":4428,"activeCount":99},[],{"trials":4430,"activeCount":99},[4431],{"nctId":4391,"briefTitle":4392,"status":167,"phases":4432,"primaryCompletion":1233,"completion":1233,"start":2613,"enrollment":33,"conditions":4433,"interventions":4434},[],[1237],[4376,4396,4397,4398],{"intervention":4398,"totalTrials":95,"cells":4436},{"EARLY_PHASE1":4437,"PHASE1":4439,"PHASE2":4441,"PHASE3":4443,"PHASE4":4445,"NA":4447},{"trials":4438,"activeCount":99},[],{"trials":4440,"activeCount":99},[],{"trials":4442,"activeCount":99},[],{"trials":4444,"activeCount":99},[],{"trials":4446,"activeCount":99},[],{"trials":4448,"activeCount":99},[4449],{"nctId":4391,"briefTitle":4392,"status":167,"phases":4450,"primaryCompletion":1233,"completion":1233,"start":2613,"enrollment":33,"conditions":4451,"interventions":4452},[],[1237],[4376,4396,4397,4398],{"intervention":4165,"totalTrials":95,"cells":4454},{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4459,"PHASE3":4461,"PHASE4":4463,"NA":4465},{"trials":4456,"activeCount":99},[],{"trials":4458,"activeCount":99},[],{"trials":4460,"activeCount":99},[],{"trials":4462,"activeCount":99},[],{"trials":4464,"activeCount":99},[],{"trials":4466,"activeCount":99},[4467],{"nctId":4158,"briefTitle":4159,"status":167,"phases":4468,"primaryCompletion":697,"completion":4161,"start":4162,"enrollment":113,"conditions":4469,"interventions":4470},[92],[1274,35,24,1275,32],[4165,4166,4167,4168],{"intervention":4167,"totalTrials":95,"cells":4472},{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4477,"PHASE3":4479,"PHASE4":4481,"NA":4483},{"trials":4474,"activeCount":99},[],{"trials":4476,"activeCount":99},[],{"trials":4478,"activeCount":99},[],{"trials":4480,"activeCount":99},[],{"trials":4482,"activeCount":99},[],{"trials":4484,"activeCount":99},[4485],{"nctId":4158,"briefTitle":4159,"status":167,"phases":4486,"primaryCompletion":697,"completion":4161,"start":4162,"enrollment":113,"conditions":4487,"interventions":4488},[92],[1274,35,24,1275,32],[4165,4166,4167,4168],{"intervention":4168,"totalTrials":95,"cells":4490},{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4495,"PHASE3":4497,"PHASE4":4499,"NA":4501},{"trials":4492,"activeCount":99},[],{"trials":4494,"activeCount":99},[],{"trials":4496,"activeCount":99},[],{"trials":4498,"activeCount":99},[],{"trials":4500,"activeCount":99},[],{"trials":4502,"activeCount":99},[4503],{"nctId":4158,"briefTitle":4159,"status":167,"phases":4504,"primaryCompletion":697,"completion":4161,"start":4162,"enrollment":113,"conditions":4505,"interventions":4506},[92],[1274,35,24,1275,32],[4165,4166,4167,4168],{"intervention":4508,"totalTrials":95,"cells":4509},"Magnevist®",{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4516,"PHASE4":4518,"NA":4520},{"trials":4511,"activeCount":99},[],{"trials":4513,"activeCount":99},[],{"trials":4515,"activeCount":99},[],{"trials":4517,"activeCount":99},[],{"trials":4519,"activeCount":99},[],{"trials":4521,"activeCount":99},[4522],{"nctId":4523,"briefTitle":4524,"status":167,"phases":4525,"primaryCompletion":4526,"completion":4527,"start":4528,"enrollment":257,"conditions":4529,"interventions":4536},"NCT02057874","3-Tesla MRI Response to TACE in HCC (Liver Cancer)",[92],"2015-11-19","2015-12-04","2014-02",[4530,4531,4532,4533,4534,4535],"Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Localized Resectable Adult Primary Liver Cancer","Localized Unresectable Adult Primary Liver Cancer","Stage A Adult Primary Liver Cancer (BCLC)","Stage B Adult Primary Liver Cancer (BCLC)",[4508],{"intervention":4127,"totalTrials":95,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4545,"PHASE4":4547,"NA":4549},{"trials":4540,"activeCount":99},[],{"trials":4542,"activeCount":99},[],{"trials":4544,"activeCount":99},[],{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[],{"trials":4550,"activeCount":99},[4551],{"nctId":4119,"briefTitle":4120,"status":167,"phases":4552,"primaryCompletion":40,"completion":4122,"start":2254,"enrollment":4123,"conditions":4553,"interventions":4554},[],[4125],[4127,1147],{"intervention":4556,"totalTrials":95,"cells":4557},"metformin hydrochloride",{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4562,"PHASE3":4564,"PHASE4":4566,"NA":4568},{"trials":4559,"activeCount":99},[],{"trials":4561,"activeCount":99},[],{"trials":4563,"activeCount":99},[],{"trials":4565,"activeCount":99},[],{"trials":4567,"activeCount":99},[],{"trials":4569,"activeCount":99},[4570],{"nctId":4571,"briefTitle":4572,"status":167,"phases":4573,"primaryCompletion":342,"completion":746,"start":2561,"enrollment":439,"conditions":4574,"interventions":4575},"NCT00984490","Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery",[92],[15],[4556],{"intervention":4577,"totalTrials":95,"cells":4578},"DNA and tissue microarray analysis",{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4580,"activeCount":99},[],{"trials":4582,"activeCount":99},[],{"trials":4584,"activeCount":99},[],{"trials":4586,"activeCount":99},[],{"trials":4588,"activeCount":99},[],{"trials":4590,"activeCount":99},[4591],{"nctId":4592,"briefTitle":4593,"status":167,"phases":4594,"primaryCompletion":1861,"completion":1861,"start":4595,"enrollment":4596,"conditions":4597,"interventions":4598},"NCT00898742","Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and\u002For Metastatic Head and Neck Cancer",[],"2007-04",58,[21],[4577,4599],"reverse transcriptase-polymerase chain reaction",{"intervention":4599,"totalTrials":95,"cells":4601},{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4603,"activeCount":99},[],{"trials":4605,"activeCount":99},[],{"trials":4607,"activeCount":99},[],{"trials":4609,"activeCount":99},[],{"trials":4611,"activeCount":99},[],{"trials":4613,"activeCount":99},[4614],{"nctId":4592,"briefTitle":4593,"status":167,"phases":4615,"primaryCompletion":1861,"completion":1861,"start":4595,"enrollment":4596,"conditions":4616,"interventions":4617},[],[21],[4577,4599],{"intervention":4181,"totalTrials":95,"cells":4619},{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4621,"activeCount":99},[],{"trials":4623,"activeCount":99},[],{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[],{"trials":4631,"activeCount":99},[4632],{"nctId":4170,"briefTitle":4171,"status":4172,"phases":4633,"primaryCompletion":4174,"completion":4175,"start":3149,"enrollment":4176,"conditions":4634,"interventions":4635},[92],[4178,4179],[4181,1411,1410,4182,4183,4184],{"intervention":4182,"totalTrials":95,"cells":4637},{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4639,"activeCount":99},[],{"trials":4641,"activeCount":99},[],{"trials":4643,"activeCount":99},[],{"trials":4645,"activeCount":99},[],{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":99},[4650],{"nctId":4170,"briefTitle":4171,"status":4172,"phases":4651,"primaryCompletion":4174,"completion":4175,"start":3149,"enrollment":4176,"conditions":4652,"interventions":4653},[92],[4178,4179],[4181,1411,1410,4182,4183,4184],{"intervention":4183,"totalTrials":95,"cells":4655},{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4660,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4657,"activeCount":99},[],{"trials":4659,"activeCount":99},[],{"trials":4661,"activeCount":99},[],{"trials":4663,"activeCount":99},[],{"trials":4665,"activeCount":99},[],{"trials":4667,"activeCount":99},[4668],{"nctId":4170,"briefTitle":4171,"status":4172,"phases":4669,"primaryCompletion":4174,"completion":4175,"start":3149,"enrollment":4176,"conditions":4670,"interventions":4671},[92],[4178,4179],[4181,1411,1410,4182,4183,4184],{"intervention":4184,"totalTrials":95,"cells":4673},{"EARLY_PHASE1":4674,"PHASE1":4676,"PHASE2":4678,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4675,"activeCount":99},[],{"trials":4677,"activeCount":99},[],{"trials":4679,"activeCount":99},[],{"trials":4681,"activeCount":99},[],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[4686],{"nctId":4170,"briefTitle":4171,"status":4172,"phases":4687,"primaryCompletion":4174,"completion":4175,"start":3149,"enrollment":4176,"conditions":4688,"interventions":4689},[92],[4178,4179],[4181,1411,1410,4182,4183,4184],{"intervention":1180,"totalTrials":95,"cells":4691},{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4696,"PHASE3":4698,"PHASE4":4700,"NA":4702},{"trials":4693,"activeCount":99},[],{"trials":4695,"activeCount":99},[],{"trials":4697,"activeCount":99},[],{"trials":4699,"activeCount":99},[],{"trials":4701,"activeCount":99},[],{"trials":4703,"activeCount":99},[4704],{"nctId":1171,"briefTitle":1172,"status":207,"phases":4705,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":4706,"interventions":4707},[],[18],[1180,1181],{"intervention":1344,"totalTrials":95,"cells":4709},{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4714,"PHASE3":4716,"PHASE4":4718,"NA":4720},{"trials":4711,"activeCount":99},[],{"trials":4713,"activeCount":99},[],{"trials":4715,"activeCount":99},[],{"trials":4717,"activeCount":99},[],{"trials":4719,"activeCount":99},[],{"trials":4721,"activeCount":99},[4722],{"nctId":1337,"briefTitle":1338,"status":153,"phases":4723,"primaryCompletion":1340,"completion":1340,"start":771,"enrollment":99,"conditions":4724,"interventions":4725},[],[1342],[71,1344,1258,1259,288],{"intervention":4727,"totalTrials":95,"cells":4728},"protein analysis",{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4735,"PHASE4":4737,"NA":4739},{"trials":4730,"activeCount":99},[],{"trials":4732,"activeCount":99},[],{"trials":4734,"activeCount":99},[],{"trials":4736,"activeCount":99},[],{"trials":4738,"activeCount":99},[],{"trials":4740,"activeCount":99},[4741],{"nctId":4742,"briefTitle":4743,"status":207,"phases":4744,"primaryCompletion":1639,"completion":1639,"start":1713,"enrollment":4745,"conditions":4746,"interventions":4747},"NCT00900003","Studying Biomarkers in Patients With Pancreatic Cancer",[],53,[821],[4727],{"intervention":1198,"totalTrials":95,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4751,"activeCount":99},[],{"trials":4753,"activeCount":99},[],{"trials":4755,"activeCount":99},[],{"trials":4757,"activeCount":99},[],{"trials":4759,"activeCount":99},[],{"trials":4761,"activeCount":99},[4762],{"nctId":1192,"briefTitle":1193,"status":207,"phases":4763,"primaryCompletion":830,"completion":830,"start":1195,"enrollment":1141,"conditions":4764,"interventions":4765},[],[27],[1198,287],{"intervention":4767,"totalTrials":95,"cells":4768},"DNA Microarray analysis",{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4770,"activeCount":99},[],{"trials":4772,"activeCount":99},[],{"trials":4774,"activeCount":99},[],{"trials":4776,"activeCount":99},[],{"trials":4778,"activeCount":99},[],{"trials":4780,"activeCount":99},[4781],{"nctId":4782,"briefTitle":4783,"status":167,"phases":4784,"primaryCompletion":1140,"completion":1140,"start":760,"enrollment":4785,"conditions":4786,"interventions":4787},"NCT00898430","Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy",[],49,[21],[4767,4788,4789],"MALDI-TOF mass spectrometry","DNA microarray and MALDI-TOF mass spectrometry",{"intervention":4788,"totalTrials":95,"cells":4791},{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4793,"activeCount":99},[],{"trials":4795,"activeCount":99},[],{"trials":4797,"activeCount":99},[],{"trials":4799,"activeCount":99},[],{"trials":4801,"activeCount":99},[],{"trials":4803,"activeCount":99},[4804],{"nctId":4782,"briefTitle":4783,"status":167,"phases":4805,"primaryCompletion":1140,"completion":1140,"start":760,"enrollment":4785,"conditions":4806,"interventions":4807},[],[21],[4767,4788,4789],{"intervention":4789,"totalTrials":95,"cells":4809},{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4814,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4811,"activeCount":99},[],{"trials":4813,"activeCount":99},[],{"trials":4815,"activeCount":99},[],{"trials":4817,"activeCount":99},[],{"trials":4819,"activeCount":99},[],{"trials":4821,"activeCount":99},[4822],{"nctId":4782,"briefTitle":4783,"status":167,"phases":4823,"primaryCompletion":1140,"completion":1140,"start":760,"enrollment":4785,"conditions":4824,"interventions":4825},[],[21],[4767,4788,4789],{"intervention":4827,"totalTrials":95,"cells":4828},"Post-operative adjuvant therapy",{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4833,"PHASE3":4835,"PHASE4":4837,"NA":4839},{"trials":4830,"activeCount":99},[],{"trials":4832,"activeCount":99},[],{"trials":4834,"activeCount":99},[],{"trials":4836,"activeCount":99},[],{"trials":4838,"activeCount":99},[],{"trials":4840,"activeCount":99},[4841],{"nctId":4842,"briefTitle":4843,"status":207,"phases":4844,"primaryCompletion":2149,"completion":2149,"start":4845,"enrollment":4846,"conditions":4847,"interventions":4848},"NCT00647218","Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer",[92],"2000-02",38,[15],[4827,4849,4850],"neoadjuvant therapy","Hormonal Therapy",{"intervention":4849,"totalTrials":95,"cells":4852},{"EARLY_PHASE1":4853,"PHASE1":4855,"PHASE2":4857,"PHASE3":4859,"PHASE4":4861,"NA":4863},{"trials":4854,"activeCount":99},[],{"trials":4856,"activeCount":99},[],{"trials":4858,"activeCount":99},[],{"trials":4860,"activeCount":99},[],{"trials":4862,"activeCount":99},[],{"trials":4864,"activeCount":99},[4865],{"nctId":4842,"briefTitle":4843,"status":207,"phases":4866,"primaryCompletion":2149,"completion":2149,"start":4845,"enrollment":4846,"conditions":4867,"interventions":4868},[92],[15],[4827,4849,4850],{"intervention":4850,"totalTrials":95,"cells":4870},{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4875,"PHASE3":4877,"PHASE4":4879,"NA":4881},{"trials":4872,"activeCount":99},[],{"trials":4874,"activeCount":99},[],{"trials":4876,"activeCount":99},[],{"trials":4878,"activeCount":99},[],{"trials":4880,"activeCount":99},[],{"trials":4882,"activeCount":99},[4883],{"nctId":4842,"briefTitle":4843,"status":207,"phases":4884,"primaryCompletion":2149,"completion":2149,"start":4845,"enrollment":4846,"conditions":4885,"interventions":4886},[92],[15],[4827,4849,4850]]